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ABSTRACT 
 
Signaling through the Epidermal Growth Factor Receptor (EGFR) plays an 
important role in both physiological and cancer-related processes. In this work, 
single-molecule microscopy measurements and computational modeling were 
closely integrated to better understand the mechanisms that regulate EGFR 
signaling. Technical improvements were made over the previously described 
Single-Molecule Pull-down (SiMPull) assay to facilitate direct detection of the 
phosphorylation state of thousands of individual receptors, and thereby estimate 
both the fraction of receptors phosphorylated at specific tyrosine residues and 
the frequency of multisite phosphorylation. These improvements enabled the first 
direct detection of multisite phosphorylation on full-length Epidermal Growth 
Factor Receptor (EGFR), and revealed that the extent of phosphorylation varied 
by tyrosine residue (biased phosphorylation). To help in understanding the 
underlying processes giving rise to these observations, a rule-based model for 
EGFR signaling was developed. The model suggested that biased 
phosphorylation could be explained by variations in adaptor protein abundances. 
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This prediction arises from the structure of the model, in which a phospho-site 
that is bound by an adaptor protein is sterically protected from the action of 
phosphatases. Testing model predictions confirmed that overexpression of the 
adaptor protein Grb2 leads to phosphorylation levels enhanced specifically at a 
site where this protein binds. Finally, this model was extended to explore the 
possible mechanisms leading to differential signaling induced by EGFR ligands. 
Model results suggest that ligand-dependent differences in dimer lifetimes lead to 
differential multisite phosphorylation and ubiquitination, which in turn could 
influence signaling kinetics and cellular outcomes. 
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Chapter 1 : Introduction 
 
1.1 Overview 
Complex multicellular organisms, such as the human body, depend on the 
ability of its individual cells to respond in a precise and coordinated fashion to 
stimuli coming either from other cells or from the surrounding environment. The 
transmission of stimuli from the exterior of the cell to its interior occurs through a 
process called signal transduction or cell signaling. For example, binding of 
ligands to membrane receptors starts a cascade of molecular events, such as 
protein phosphorylation and interactions, that propagate the signal to the nucleus 
and eventually lead to cellular responses. Even though the overall picture of 
many signal transduction pathways is known, many critical details remain poorly 
understood. One such detail is the heterogeneity in the activation states of 
molecules participating in signal transduction, a feature that cannot be provided 
by commonly used ensemble techniques. To address this issue, a single-
molecule microscopy technique was improved, allowing for access to this kind of 
information. The work presented here focuses in the study of activation states of 
the Epidermal Growth Factor Receptor (EGFR). Additionally, computational 
models were used to help understanding the underlying processes giving rise to 
the observed distribution of activated states. 
In this introduction, some of the features of the EGFR signaling pathway 
are described, including signal initiation, transmission and regulation. Next, the 
advantages and limitations of ensemble and single-molecule techniques are 
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discussed. Then, some of the previous work relating to modeling of EGFR 
signaling and the current advances in modeling techniques is described.  The 
final part of this section contains the central hypothesis for this work and a 
summary of the results obtained. 
 
1.2 Signaling through the Epidermal Growth Factor Receptor 
1.2.1 Introduction 
The Epidermal Growth Factor Receptor (EGFR) belongs to the 
EGFR/erbB family of Receptor Tyrosine Kinases, which consists of four 
members: EGFR (erbB1, HER1), HER2 (erbB2), HER3 (erbB3), and HER4 
(erbB4). In general, these proteins are single-pass transmembrane proteins with 
an extracellular ligand binding domain and a cytoplasmic tail containing a 
tyrosine kinase domain (Figure 1.1) (Lemmon and Schlessinger, 2010; Yarden 
and Sliwkowski, 2001). As exceptions, HER2 has no known ligand, and HER3 
kinase activity is dependent on initial activation by HER2 (Steinkamp et al., 
2014). Ligand binding to these transmembrane proteins leads to conformational 
changes, receptor homo- and hetero-dimerization, kinase activation and the 
transphosphorylation of multiple cytoplasmic tail tyrosines (Schlessinger, 2002). 
These phosphotyrosines in turn provide sites for the recruitment and activation of 
cytoplasmic proteins, initiating signaling cascades that control numerous cellular 
processes such as gene expression, cell migration and cell division. 
Dysregulation of EGFR signaling, commonly caused by receptor overexpression 
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and/or mutation, has been associated with development and progression of 
cancer. 
 
Figure 1.1. Ligand-induced EGFR dimerization and activation. EGFR ligands 
include EGF, TGF-α and epiregulin. 
In recent years there has been growing evidence that suggests that EGFR 
activation may not only form dimers, but also tetramers and higher-order 
oligomers (Kozer et al., 2014, 2013a). Considering that most of the available 
information about EGFR activation relates to receptor dimerization, this study 
focuses on this form of signal initiation.  
1.2.2 Recruitment of adaptor proteins to activated receptors  
Activated EGFR is capable of recruiting a variety of adaptor proteins that 
have different roles in signal transduction and regulation of cellular outcomes. A 
few examples of these proteins and the specific sites to which they bind is 
displayed in Figure 1.2a.  The first part of this dissertation focuses on the study of 
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the phosphorylation of tyrosines 1068 and 1173, and the recruitment of Grb2 and 
Shc1 to these sites (Figure 1.2b). Proteins recruited to the receptor can be 
phosphorylated either by EGFR or by other kinases such as Src. Grb2 can bind 
to phosphorylated Shc1, and therefore be recruited to the receptor indirectly 
through Shc1 (Batzer et al., 1994). Even though both Y1068 and Y1173 can 
recruit Grb2, either directly or indirectly, and lead to activation of MAPK pathway, 
these sites have distinct additional roles in signaling. For example, pY1173 can 
also recruit and activate PLC-γ and calcium signaling, or recruit the phosphatase 
Shp1, as shown in Figure 1.2a. On the other hand, pY1068 has been shown to 
be essential for efficient recruitment of the E-3 ubiquitin ligase Cbl, which 
ubiquitinates EGFR and mediates its downregulation (Sigismund et al., 2013). 
The interaction of Grb2 and Cbl, and the proximity of their recruitment 
sites, seems to give rise to a cooperative behavior in which the stability of the 
Cbl-Grb2 complex is higher than that of the individual proteins (Figure 1.2c). 
Chapter 5 of this dissertation focuses on the computational modeling of this 
interaction, and how differences in stability of receptor dimers induced by distinct 
EGFR ligands could regulate this interaction, and eventually lead to different 
signaling behavior. 
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Figure 1.2. Recruitment capacity of activated EGFR. Description. (a) 
Representation of some of the adaptor proteins recruited to activated EGFR. 
Based on (Olayioye et al., 2000). (b) Sites and interactions considered for first 
part of this dissertation. (c) Sites and interactions considered in Chapter 5. Cbl 
and Grb2 can interact. 
 
1.2.3 Protein tyrosine phosphatases (PTPs) and EGFR signaling 
Phosphorylation levels are the net result of protein phosphorylation and 
dephosphorylation. A phosphate group can be added at the amino acid residues 
tyrosine, serine or threonine. In the case of phosphorylated tyrosines, in which 
this dissertation focuses, protein tyrosine phosphatases (PTPs) are the 
responsible for removing the phosphate groups from this amino acid.  PTPs play 
a very important role in regulating EGFR signaling, both before and during ligand 
stimulation. For example, in many cell types phosphorylation of receptor tyrosine 
kinases (RTKs) is undetectable in the absence of ligand, but inhibition of PTPs 
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results in important levels of receptor phosphorylation (Jallal et al., 1992; Tarcic 
et al., 2009). This basal phosphorylation, which is thought to originate from short 
interactions between unliganded receptors, is suppressed by constantly active 
phosphatases. Phosphatase activity can be regulated both in time and space. 
For example, while DEP-1 causes receptor dephosphorylation at the membrane, 
PTP1B seems to mainly locate and cause EGFR dephosphorylation at 
endosomes (Tarcic et al., 2009; Eden et al., 2010; Yudushkin et al., 2007). Even 
though most PTPs are known to downregulate EGFR signaling, there are 
examples where a phosphatase can enhance downstream signaling (Yao et al., 
2017). 
The timescale of phosphorylation and dephosphorylation events was 
recently informed by a combination of experimental and computational modeling 
techniques (Kleiman et al., 2011). Kleiman et al. showed that activated EGFR is 
quickly dephosphorylated after a few seconds of adding a fast-binding kinase 
inhibitor. Their modeling results suggest that receptors can go through hundreds 
of phosphorylation/dephosphorylation cycles in the order of a few minutes. Each 
of these events require energy in the form of ATP. A fast dynamic interplay 
between these two processes is essential for allowing the cell to respond in a 
prompt manner to external stimuli and to prevent spurious and excessive 
signaling. 
1.2.4 Regulation of EGFR signaling by endocytosis 
EGFR signaling can be regulated both in time and space. After activation, 
receptors at the plasma membrane are internalized into endocytic vesicles. 
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Recent studies suggest that receptors at endosomes cannot activate MAPK 
pathway, the reason being that Ras, a protein required for MAPK activation, is 
mainly located at the plasma membrane and not in endosomes (Pinilla-Macua et 
al., 2016). The fate of internalized receptors is regulated by a complex network of 
proteins, including components of the ESCRT (endosomal sorting complexes 
required for transport) machinery and members of the Rab GTPase family 
(Sorkin and Goh, 2009; Schwartz et al., 2007). Depending on different factors, 
receptors can be recycled back to the plasma membrane, where they can 
continue signaling, or they can be targeted for lysosomal degradation, causing 
signal downregulation. One of the main factors regulating the fate of EGFR is 
receptor ubiquitination, which in the case of EGFR is mediated by the E3-
ubiquitin ligase Cbl (Levkowitz et al., 1999). Receptor fate is determined by the 
levels and/or type of ubiquitination, which are recognized by Ubiquitin-interacting 
motifs (UIMs) present in proteins involved in receptor sorting (Raiborg and 
Stenmark, 2009; Huang et al., 2013). The level of ubiquitination and receptor fate 
seems to be dependent on ligand type and dose (Roepstorff et al., 2009; 
Sigismund et al., 2013). A more in depth discussion about the literature relating 
to ligand type- and dose-dependent regulation of endocytosis and signaling is 
presented in Chapter 5. 
 
1.3 Comparison between ensemble and single-molecule techniques  
There are two broad types of techniques that can be used to study protein 
interactions and PTMs (post-translational modifications): ensemble and single-
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molecule techniques. In ensemble techniques, the average state of a (generally 
large) group of molecules is measured. Examples of this type of techniques 
include Western blot and ELISA (enzyme-linked immunosorbent assay), which 
measure the relative level of protein interaction- or PTM-state. Single-molecule 
techniques on the other hand are able to distinguish the state of individual 
molecules. Single-molecule microscopy and atomic force microscopy represent 
two of the most used techniques in this category.  
 Both ensemble and single-molecule techniques have their advantages 
and limitations, therefore choice of method depends on different factors such as 
considering the level of information that wants to be obtained and the availability 
of resources, to name a few. In terms of practicality and cost, ensemble 
techniques generally trump. Single-molecule assays generally require costly 
equipment and high-level of expertise. Nevertheless, they often provide 
information otherwise inaccessible. There are many examples of the power of 
single-molecule level measurements to reveal mechanistic details that could not 
be studied using ensemble techniques (Oh et al., 2012; Low-Nam et al., 2011; 
Munsky et al., 2012; Andrews et al., 2008). Recently, Jain et al. developed a 
technique called Single-Molecule Pull-down (SiMPull), which allows to assess the 
composition of individual molecular complexes (Jain et al., 2011). Later in this 
work, a series of modifications to this technique are described. These 
modifications allowed for the quantification of phosphorylation states from 
thousands of individual membrane receptors. 
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1.4 Computational modeling of EGFR signaling 
The vast amount of experimental data available about EGFR activation 
and its downstream signaling events has made it a perfect system for 
mathematical and computational studies (Kholodenko et al., 1999; Blinov et al., 
2006; Shankaran et al., 2012). In spite of this body of knowledge, many of the 
mechanisms involved in EGFR activation and its regulation are not completely 
understood. Modeling of EGFR signaling was generally performed using a series 
of simplifications. For example, even though it is known that different 
phosphorylated residues in EGFR recruit specific adaptor proteins and have 
different functions, these different sites were generally represented as a single 
one, for which multiple adaptor would compete for (Figure 1.3a). These 
simplifications were in most cases justified, not using them could easily result in 
the need of defining hundreds of ordinary differential equations, a process that 
would be error-prone and time-consuming. The relatively recent development of 
tools that allow for rule-based modeling of biochemical networks has made 
possible modeling of signaling systems without the need of employing the 
aforementioned simplifications (Faeder et al., 2009; Smith et al., 2012). 
In this type of modeling, the user define rules containing only the protein 
components that are relevant for the reaction to happen, and the open source 
software does the work of creating a reaction for every possible species that is 
able to participate in the reaction. In the example presented in Figure 1.3, the 
user only needs to define 18 rules total, and the software generates ordinary 
differential equations (ODEs) for the 729 possible different species. In this work, 
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this powerful computational technique was used to include site-specific 
information about EGFR phosphorylation and recruitment of adaptor proteins. 
 
Figure 1.3. Comparison of traditional vs rule-based modeling approaches. (a) 
Traditional models generally lump sites together to prevent the need to define a 
high number of ordinary differential equations (ODEs). (b) Simplified 
representation of rule-based model considering phosphorylation, 
dephosphorylation and reversible adaptor protein binding to six tyrosine residues. 
The three possible states for each site are unphosphorylated, phosphorylated-
free, or phosphorylated-occupied (by adaptor protein).  
 
1.5 Hypothesis 
My central hypothesis is that upon EGFR activation there are subsets of 
receptors having distinct phosphorylation patterns and therefore playing different 
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roles in signal propagation. To test this hypothesis, a series of improvements 
were made to the SiMPull technique, allowing the analysis of phosphorylation 
states from thousands of receptors. Since phosphorylation kinetics is the result of 
a variety of molecular processes, computational modeling was used to aid in the 
quest to understand how the interrelation between these events give rise to the 
observed behavior. 
 
1.6 Summary of Results 
Chapter 2 provides a detailed description of the improvements made to 
the SiMPull technique for quantification of receptor multisite phosphorylation. 
Results show that only a subpopulation of EGFR become phosphorylated under 
what is considered maximal activation conditions and that the extent of 
phosphorylation varies by tyrosine residue. Three-color imaging of EGFR-GFP 
with antibodies directed to two distinct phospho-sites revealed the presence of a 
subset of receptors with simultaneous phosphorylation at the two sites probed. 
Chapter 3 describes the development of a rule-based model for the initial 
steps of EGFR signaling. Particularly, it considers ligand-induced receptor 
activation and the recruitment of the adaptor proteins Grb2 and Shc1 to 
phosphorylated tyrosines 1068 and 1173 in EGFR, respectively. In Chapter 4, 
the model was fine-tuned with experimental data obtained with the improved 
SiMPull technique. Experimental testing of model predictions confirmed that 
adaptor proteins are able to protect the sites to which they bind from 
dephosphorylation, and therefore modulate the phosphorylation patterns 
12 
 
observed in vivo. Chapter 5 describes an extended model developed to help 
explain differential signaling induced by EGFR ligands.  The model provides 
testable predictions to help dissect the roles of dimer lifetimes and ubiquitination 
in this differential signaling. Finally, Chapter 6 provides a brief discussion about 
the implications that these results have in the understanding of signaling 
pathways, and some of the possible future directions. 
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Chapter 2 : Single Molecule Pull-down for Quantification of 
Membrane Receptor Multisite Phosphorylation 
 
Emanuel Salazar-Cavazos1,2, Keith A Lidke2,3, Diane S. Lidke1,2 
1Department of Pathology, 2Comprehensive Cancer Center and 3Department of 
Physics & Astronomy, University of New Mexico, Albuquerque, NM 87131 
2.1 Introduction 
The ability of a cell to respond rapidly and specifically to changes in the 
surrounding environment is controlled by protein-protein interactions at the 
plasma membrane and along the signaling cascade. While much is known about 
the biochemical events that govern signaling pathways, this information has 
mostly been derived from population-based measurements that typically average 
over millions of cells and/or proteins. However, there is growing evidence that the 
heterogeneity of the system contributes to how cellular information is processed 
(Lahav et al., 2004; Feinerman et al., 2008; Coba et al., 2009; Spencer et al., 
2009).  To better understand the role of protein phosphorylation heterogeneity in 
directing signaling outcomes, the single molecule pull down (SiMPull) assay was 
adapted to identify the phosphorylation state of individual receptors.   
SiMPull is a powerful technique that allows for interrogation of 
macromolecular complexes at the individual protein level.  Jain et al. first 
demonstrated the ability of this technique to capture macromolecular complexes 
(Jain et al., 2011).  SiMPull samples are prepared in a manner similar to 
IP/Western Blot protocols, but the sample is interrogated using single molecule 
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microscopy. Briefly, cells are lysed and the protein of interest is captured by 
antibodies bound to the coverglass. If the proteins are fluorescently tagged, 
either by fluorescent proteins or subsequent antibody labeling, their presence will 
be quantified by single molecule imaging (Figure 2.1A).  
Here, a modification of SiMPull for the study of phosphorylation patterns of 
transmembrane receptors is described. Traditionally, protein phosphorylation has 
been measured using ensemble techniques, such as Western Blot analysis or 
flow cytometry, which provide information on the relative changes of a protein 
phosphorylation amount.  However, these techniques cannot determine the 
fractions of proteins in a specific phosphorylation state, much less identify when 
an individual protein contains multiple sites of phosphorylation.  While mass 
spectrometry has the potential to detect multisite phosphorylation, the residues of 
interest must be found in the same small peptide that is generated by enzymatic 
digestion (typically 7-35 amino acids) or the protein of interest must be small 
(Swaney et al., 2010; Curran et al., 2015; Brunner et al., 2015). Therefore, new 
techniques are needed to better understand the phosphorylation status of 
individual proteins. Recently, Kim et al. used a modified SiMPull approach, 
termed SiMBlot, to pull-down surface biotinylated proteins and identify 
phosphorylation using denaturing conditions and phosphorylation-specific 
antibody labeling (Kim et al., 2016).  Our approach differs in several significant 
ways from SiMBlot and provides important improvements over previous protocols 
(Jain et al., 2012; Kim et al., 2016), including the reduction of autofluorescence in 
the green spectral channel and a simplified imaging chamber that accommodates 
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higher sample number with lower sample volume. Results demonstrate the 
importance of optimizing antibody labeling and fixation conditions.  To quantify 
receptor phosphorylation, two- and three-color imaging were used to identify 
individual proteins and their corresponding phosphorylation status.  Corrections 
to account for membrane receptor surface expression and steric hindrance in the 
case of dual antibody labeling are described.   
This method was applied to the study of the classical Epidermal Growth 
Factor Receptor (EGFR).  EGFR has 20 tyrosines in its cytoplasmic tail, at least 
12 of which are known to recruit specific adaptor proteins (Schulze et al., 2005). 
The potential for multisite phosphorylation provides a mechanism through which 
the cell might differentially respond to extracellular cues, depending on the extent 
and combination of receptor phosphorylation (Gibson et al., 2000; Salazar and 
Höfer, 2009; Coba et al., 2009; Lau et al., 2011). Results showed that only a 
subpopulation of EGFR become phosphorylated under what is considered 
maximal activation conditions and that the extent of phosphorylation varies by 
tyrosine residue. Multiplex imaging of the GFP-tagged receptors and antibodies 
directed to two distinct phosphotyrosines revealed that multisite phosphorylation 
frequently occurs.  The extent of phosphorylation at individual tyrosines along 
with the existence of multisite phosphorylation has implications for how EGFR 
translates extracellular cues into downstream signaling outcomes.  
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Figure 2.1. SiMPull to quantify protein phosphorylation. (A) Illustration depicting 
overall principle for assessing phosphorylation at the single molecule level using 
GFP-tagged EGFR (EGFR-GFP) as an example. (B) Representative images 
showing raw data (top) and blob-reconstructed localized molecules (bottom). 
CHO-EGFR-GFP cells were stimulated for 5 min with 25 nM EGF at 37°C before 
lysis for SiMPull. Raw images are brightness and contrast enhanced for 
visualization. The EGFR-GFP fits were filtered based on their fit to the 
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microscope point spread function and the GFP-channel used as a mask to create 
the overlay. The number in the bottom right image represents the 
phosphorylation percentage estimated for this field of view.  (C) Hydrophobic 
array for preparation of SiMPull samples. 
 
2.2 Results 
2.2.1 Visualization of individual protein phosphorylation status by SiMPull 
Phosphorylation of EGFR was assayed at the single molecule level using 
the SiMPull concept depicted in Figure 2.1A, where the GFP-tagged receptors 
from cell lysates are immunoprecipitated by antibodies bound to the coverglass 
and subsequently labeled with fluorescently-tagged antibodies detecting 
phosphorylated tyrosines (anti-PY).  Figure 2.1B shows the capture of single 
EGFR-GFP from cell lysate on the coverglass surface and the corresponding 
labeling of phosphorylated EGFR using a pan-phosphotyrosine antibody 
conjugated to Alexa Fluor 647 (anti-PY AF647; PY99 antibody). Individual 
molecules are identified in each image (Figure 2.1B).  Images are then overlaid 
to identify phosphorylated receptors. Colocalization of receptor and PY 
localizations provide an initial estimate of the fraction of phosphorylated 
receptors (Figure 2.1B). Optimization of the experimental process and image 
analysis, including reduction in autofluorescence, corrections for the level of 
receptor surface expression and the appropriate antibody labeling conditions, are 
described in the following sections. 
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2.2.2 Simplified sample chamber increases throughput and reduces sample 
volume 
Jain et al. originally described the use of a fluidic chamber for imaging that 
consisted of 4-6 channels generated between a coverglass and microscope slide 
using epoxy (Jain et al., 2012).  While these types of flow chambers are 
straightforward to produce, the protocol is time consuming (30-60 min) and larger 
volumes (~70 µL) are required to fill each channel. To overcome these 
limitations, a hydrophobic barrier pen was used to create an array of isolated 
sample regions on a coverglass (Figure 2.1C). Rectangular (24x60mm, #1.5) 
coverglasses are treated as described and an array of up to 20 squares can be 
drawn with the hydrophobic ink pen in a matter of minutes.  As little as 10 µL of 
sample is needed to fill each region, which is seven times less than for the 
original flow channels. This is particularly useful considering the high cost of 
fluorescently labeled antibodies and that for some applications sample availability 
may be limited.  Time for sample preparation is also reduced as washing and 
labeling steps are simplified without the need for flowing of buffers through 
channels.   
 
2.2.3 Quenching with NaBH4 reduces background autofluorescence 
It has been previously noted that autofluorescent background is detected 
in the spectral region corresponding to green emitting fluorophores (Jain et al., 
2012). Autofluorescent puncta were also observed in the green spectral channel 
(503-548 nm), which were identified as single GFP molecules in the absence of 
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cell lysate.  Since the experimental approach used relies on GFP to identify the 
location of EGFR on the coverglass, it was important to reduce this background 
to avoid over-counting of receptors.  Incubating the PEG-coated coverglass with 
Sodium Borohydride (10 mg/mL NaBH4 for 4 min) was found to significantly 
reduce the number of background fluorescent molecules (Figure 2.2). Despite 
the improvement in background signal, background measurements were 
routinely acquired for each coverglass preparation to enable background 
correction for each experiment (see Methods for details). 
 
Figure 2.2. Reduction of autofluorescence with Sodium Borohydride (NaBH4). 
(A) Raw images and blob-reconstructions from a typical field of view of a 
PEG/PEG-biotin functionalized surface without (left) and with (right) NaBH4-
treatment. (B) Quantification of the average number of false-positive localizations 
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per field of view in surfaces with or without treatment with NaBH4. For each 
condition N > 12 fields of view were analyzed. Error bars represent mean +/- 
S.E.M. 
 
2.2.4 Antibody optimization is required for accurate phosphotyrosine 
detection 
Since antibodies are used to quantify protein phosphorylation, it is critical 
to optimize the antibody labeling protocol. Figure 2.3 presents the results from 
optimization of anti-EGFR-pY1068. In these experiments, EGF stimulated cells 
were co-treated with a phosphatase inhibitor (pervanadate, PV) to increase the 
amount of receptor phosphorylation.  Incubation of EGFR-pY1068 on ice for 60 
minutes was needed to ensure maximal labeling (Figure 2.3A). Importantly, 
results show that over time the antibody dissociates from EGFR, with ~37% 
reduction after 1 hr at room temperature (Figure 2.3B, no fixative). Complete 
imaging of the sample array can take up to 1 hr, therefore, loss of antibody over 
this period would lead to an underestimate of receptor phosphorylation for 
samples imaged later in time. Multiple fixation protocols to minimize antibody 
unbinding were tested. Results show that fixation with 4% 
Paraformaldehyde/0.1% Glutaraldehyde (PFA/GA) for 10 min stabilized the 
antibody levels for at least 1 hr (Figure 2.3B, PFA/GA). 
To ensure that saturating levels of antibody are used, concentration 
curves for each antibody were generated, using the PFA/GA fixation for optimal 
results.  The example in Figure 2.3C shows the titration curve for anti-EGFR-
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pY1068, which saturates at ~20 g/mL. Consequently, 20 g/mL were used for 
all experiments.  Binding affinity will vary for each antibody and fluorescent-
conjugation may also alter antibody affinity. Therefore, it is necessary to perform 
a binding curve for each antibody and for each new antibody conjugation. 
Another important consideration is the specificity of the antibody for its binding 
site.  Kim et al demonstrated an elegant way to determine specificity by using 
purified proteins with individual tyrosines mutated to alanine. The same EGFR-
pY1068 and EGFR-pY1173 antibodies that they found to have high specificity 
from their in vitro measurements are used in this work (Kim et al., 2016).    
 
Figure 2.3. Optimization of antibody labeling for accurate quantification of 
receptor phosphorylation. CHO-EGFR-GFP cells were pre-treated with 1 mM 
PV for 15 min and stimulated with 50 nM EGF+1mM PV for 5 min at 37°C to 
enhance receptor phosphorylation and interrogated for anti-EGFR-pY1068-
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CF555 labeling. (A) Antibody labeling with anti-pY1068 requires 60 min to reach 
maximal labeling. A 20 g/mL antibody concentration was used. Number of 
receptors analyzed per condition, N>3400. (B) Addition of PFA/GA post-fixation 
prevents loss of antibody over time. N>2700 per condition. (C) Increase in 
labeling as a function of antibody dose. EGFR-pY1068-CF555 saturates at ~20 
g/mL. Antibody was incubated for 1 hour on ice and post-fixed with PFA/GA. 
Resting cells were used as a control for non-specific labeling. N>1700 per data 
point.  Error bars are standard error of measured phosphorylation percentages. 
 
2.2.5 Correction is required to account for non-surface localized receptors 
At any point in time, a fraction of membrane receptors is trafficking 
through intracellular compartments. These internal receptors are not accessible 
during addition of extracellular ligand, but will be captured by the antibody during 
SiMPull sample preparation and result in an underestimate of receptor 
phosphorylation. In CHO-EGFR-GFP cells, a fraction of the receptors are located 
in intracellular compartments (Figure 2.4A, left). To determine the fraction of 
EGFR accessible to ligand, all surface proteins on the CHO-EGFR-GFP cells 
were labeled with membrane-impermeable AF647-NHS Ester (Figure 2.4A, right) 
and used SiMPull to visualize the amount of EGFR-GFP colocalized with AF647.  
By increasing the concentration of AF647-NHS until saturation is achieved, it was 
estimated that ~65% of the receptors are located at the plasma membrane 
(Figure 2.4B).  With this information, measurements were corrected to account 
for only those receptors available to bind ligand. After correction, ~14% of the 
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receptors are phosphorylated at Y1068 after 1 min stimulation with 50 nM EGF 
(Figure 2.4C). While surface labeling of receptors with AF647-NHS ester allows 
for identification of surface proteins, this modification reduced EGF binding (data 
not shown). Therefore, pre-labeling of receptors was not used for the study of 
EGFR activation.  
To validate the correction method, the phosphorylation levels of receptors 
were measured in CHO cells expressing ACP-tagged EGFR.  EGFR localized at 
the plasma membrane was directly labeled using membrane-impermeable CoA-
Atto488 as describe previously (Valley et al., 2015; Ziomkiewicz et al., 2013). 
Cells were then exposed to EGF and probed for EGFR phosphorylation with 
SiMPull, this time using Atto488 as the marker for plasma membrane EGFR. The 
percent of phosphorylated EGFR was similar when comparing the membrane-
localized ACP-EGFR and the membrane-corrected EGFR-GFP samples (Figure 
2.4C). Therefore, the effects of EGF binding to EGFR on the plasma membrane 
can be accurately determined from whole cell lysates using the correction, which 
was applied for the remainder of the results.   
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Figure 2.4. Correction for cellular distribution of receptors. (A) Confocal images 
showing typical distribution of EGFR-GFP in CHO cells (left) and the labeling of 
surface proteins achieved with the AF647-NHS ester (right). (B) Cells were 
incubated with increasing concentrations of AF647-NHS and assayed by SiMPull 
to determine the percentage of EGFR-GFP molecules labeled with AF647. 
Number of receptors analyzed per data point, 850 < N < 1550. (C) Percentage of 
pY1068+ receptors estimated for EGFR-GFP before and after correcting for 
surface expression.  The corrected phosphorylation percentage for EGFR-GFP 
corresponds to the value measured for ACP-EGFR, which only includes plasma 
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membrane localized receptors. N>2400 for each EGFR type.  Error bars are 
standard error of measured phosphorylation percentages. 
 
2.2.6 Extent of phosphorylation varies by tyrosine residue 
SiMPull was used to characterize the kinetics and dose response of EGFR 
activation.  The multi-well hydrophobic array (Figure 2.1C) made it possible to 
efficiently examine a full dose response or time course of activation in a single 
imaging session.  Total EGFR tyrosine phosphorylation (PY) and the 
phosphorylation patterns for two specific tyrosine sites (Y1068 and Y1173) were 
quantified.   Cells simulated for 5 min (Figure 2.5A) with increasing 
concentrations of EGF showed the expected increase in total phosphorylation 
with ligand dose (Figure 2.5A, PY, blue bars). This fraction reached 64% with 50 
nM EGF, a dose that is considered saturating. While both specific tyrosines show 
less phosphorylation than total PY, the fraction of EGFR with phosphorylation at 
Y1173 was consistently higher than at Y1068 (Figure 2.5A). The kinetics of 
phosphorylation between PY, pY1068 and pY1173 are similar (Figure 2.5B). 
These results indicate several important outcomes. First, phosphorylation 
detection by SiMPull is sensitive, capable of detecting receptor phosphorylation 
at low ligand dose and early time points. Second, even under saturating ligand 
conditions, only a fraction of receptors is phosphorylated, reaching a maximum of 
64% with 5 min stimulation. Third, the extent of phosphorylation varies by 
tyrosine residue. The detected phosphorylation levels are not due to limitations in 
antibody labeling, since cells stimulated in the presence of phosphatase 
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inhibitors showed increased receptor phosphorylation (Figure 2.6A).The use of 
high salt (500 mM NaCl) concentration during cell lysis did not change the 
detected phosphorylation, indicating that adaptor proteins are not interfering with 
antibody recognition (Figure 2.6B). 
 
Figure 2.5. The extent of phosphorylation varies by tyrosine residue. (A) Dose 
response curve for CHO-EGFR-GFP cells after 5 min of EGF addition at 37°C. 
Number of receptors analyzed per condition, 800 < N < 1800. (B) Site-specific 
EGFR phosphorylation kinetics. Phosphorylation time course for CHO-EGFR-
GFP cells stimulated with 25 nM EGF at 37°C. N>1800. Error bars are standard 
error of measured phosphorylation percentages. 
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Figure 2.6. Effect of phosphatase inhibition or cell lysate salt concentration  on 
detected phosphorylation levels. (A) CHO-EGFR-GFP cells were stimulated at 
37°C with either 50 nM EGF for 5 min or pre-treated with 1 mM pervanadate (PV) 
for 15 min and then stimulated with 50 nM EGF and 1mM PV (PV + EGF) for 5 
min. Considering that pervanadate treatment induces EGFR phosphorylation that 
may not be restricted to the plasma membrane, no surface correction was 
applied for this figure. Number of receptors per condition, 690 < N < 3400. (B) 
CHO-EGFR-GFP cells were stimulated at 37°C with 25 nM EGF for 1 min and 
protein extraction was performed with either regular lysis buffer containing 150 
mM NaCl (see Methods) or 500 mM NaCl. High NaCl concentrations have been 
shown to promote disruption of interactions between SH2-containing proteins 
and their phosphorylated binding partner sites (Grucza, R. A., et al., 
Biochemistry, 39(33), 10072-10081). 670 < N < 1600. Error bars are standard 
error of measured phosphorylation percentages. 
 
2.2.7 Three-color SiMPull reveals multisite phosphorylation 
The observation that Y1068 and Y1173 have different phosphorylation 
levels suggests that there are subpopulations of receptors with differing 
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phosphorylation patterns. However, examining a single tyrosine site at a time 
cannot address the coincidence of phosphotyrosines.  To assess the potential of 
multisite protein phosphorylation, simultaneous three-color SiMPull imaging was 
developed. To test whether receptors phosphorylated at Y1068 were also 
phosphorylated at other tyrosine residues, receptors were co-labeled with anti-
pY1068 and anti-PY antibodies. When labeling a single protein with two or more 
antibodies, the effects of steric hindrance must be considered.  In this case, 
labeling first with anti-pY1068 followed by anti-PY did not alter PY levels (Figure 
2.7A).  However, labeling with anti-PY first did cause a loss of pY1068 signal 
(Figure 2.7B). Therefore, the experiments were performed with sequential 
labeling, anti-pY1068 followed by anti-PY. As before, the addition of EGF 
resulted in increased phosphorylation, with the PY antibody showing more 
labeling than the site-specific antibody (Figure 2.8A,B) and the presence of multi-
phosphorylated receptors was observed in the three-color images (Figure 2.8A, 
white circles). Figure 2.8B shows quantification of the three-color colocalization, 
which revealed that ~12% of EGFR were labeled by both antibodies 
(pY1068+PY, orange bar). Importantly, nearly 76% of the receptors 
phosphorylated at Y1068 were co-labeled with PY.  Therefore, multisite 
phosphorylation is a prevalent outcome in EGFR activation. 
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Figure 2.7. Assessment and correction of steric hindrance in sequentially 
incubated antibodies for 3-color SiMPull. (A) Evaluation of steric hindrance 
between anti-pY1068-CF555 and anti-PY-AF647 (PY) antibodies. CHO-EGFR-
GFP cells were stimulated with 25 nM EGF for 5 min at 37°C and EGFR 
phosphorylation quantified using 3-color SiMPull.  Labeling with anti-pY1068 first 
did not reduce subsequent labeling by anti-PY. However, a reduction in pY1068+ 
receptors is seen when the labeling order is reversed. Number of receptors 
analyzed per measurement, N>800. n.s. not significant, P = 0.5187. (B) 
Evaluation of steric hindrance between anti-pY1068-CF555 and anti-pY1173-
CF640R antibodies. Cells were stimulated as described in (A) and receptor 
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phosphorylation assayed by 3-color SiMPull. A reduction in labeling was 
observed for the antibody that is applied second in the labeling sequence. N>780 
per measurement. (C) Diagram describing estimation of correction factor (α) to 
calculate actual fraction of receptors with dual phosphorylation (D’). The 
observed reduction in labeling with Antibody 1 alone (left bar) as compared to 
Antibody 1 following Antibody 2 (right bar) indicates the level of steric hindrance.  
From this information, the correction factor can be calculated. (D) Validation of 
the correction factor by exchanged labeling order. After applying the correction 
factor (“Corrected” bars), the percentage of pY1068+pY1173+ receptors is 
similar.  Error bars are standard error of measured phosphorylation percentages. 
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Figure 2.8. SiMPull reveals EGFR multisite phosphorylation. (A) Representative 
3-color SiMPull image showing detection of EGFR-GFP (cyan), where receptors 
positive for PY labeling appear purple and white circles mark receptors labeled 
for both PY and pY1068. This image does not contain receptors labeled with 
pY1068 alone. Cells were treated with 25 nM EGF for 5 min. (B) Quantification of 
single and multi-phosphorylation in EGFR.  Number of receptors analyzed per 
condition, N>500 for resting condition and N>840 for EGF condition. (C) Step-
photobleaching analysis of multi-phosphorylated EGFR-GFP from (B). The 
majority (98%) of diffraction limited GFP spots show single-step bleaching, 
consistent with the pull-down of receptors as monomers. Inset shows example 
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GFP-intensity trace of a multi-phosphorylated EGFR-GFP. (D) Percentage of 
Y1173 phosphorylation in overall population of surface receptors compared to 
that in pY1068+ receptors. N>780 for EGFR and N=51 for pY1068 EGFR. *** P < 
0.001. (E) Multisite phosphorylation is also observed at lower EGF dose.  Cells 
stimulated for 5 min with indicated EGF dose. 970 < N < 1700 per condition.  
Error bars are standard error of measured phosphorylation percentages. 
To ensure receptors detected as multi-phosphorylated were individual 
receptors labeled with both antibodies rather than two nearby labeled receptors 
detected as one in a diffraction-limited spot, step-photobleaching analysis was 
performed (Figure 2.8C). Analysis showed that the majority of doubly labeled 
receptors (~98%) were associated with a single EGFR-GFP molecule (Figure 
2.8C, right). It is important to note that the number of GFP spots demonstrating 
two-step photobleaching increased as the sample density increased (data not 
shown). Therefore, a pulldown protein density in the range of 0.04-0.08/μm2 is 
recommended.  Alternatively, photobleaching traces can be performed in each 
measurement to exclude those spots showing more than one-step 
photobleaching. 
With the knowledge that the majority of pY1068+ receptors are also 
phosphorylated in at least one other tyrosine residue, the pairwise 
phosphorylation of Y1068 and Y1173 was examined. In contrast to dual labeling 
with pY1068 and PY (pan-pTyr) antibodies, the close proximity of these two 
tyrosines did result in steric hindrance of antibody binding. This is seen as a 
reduction in labeling when the antibodies are applied second as compared to first 
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(Figure 2.7B). The reduced labeling efficiency measured in sequential labeling 
was used to correct for steric blocking (see Figure 2.7C,D and Methods). Results 
show that approximately 50% of the pY1068+ receptors are co-phosphorylated at 
Y1173. This is an enrichment of approximately two-fold as compared to pY1173+ 
in the total EGFR population (Figure 2.8D). Stimulation of cells with lower doses 
of EGF also resulted in multisite EGFR phosphorylation (Figure 2.8E). Notably, at 
1 nM EGF, multi-phosphorylation is already considerable within the site-specific 
subpopulations, with 58 +/- 14% of pY1068+ receptors and 29 +/- 8% of 
pY1173+ receptors being co-labeled with PY. Therefore, multisite 
phosphorylation is not merely a consequence of saturating ligand conditions. The 
use of a three-color imaging scheme to correlate phospho-antibody labeling 
directly with GFP-tagged receptors was critical, due to the relatively high non-
specific binding of the antibodies (Figure 2.9A,B). In the absence of the GFP 
channel to remove the non-specific binding, the values for dual labeling are 
underestimated (Figure 2.9C,D). These results show that SiMPull, when 
performed using the improvements described here, can be used to quantify the 
extent and coincidence of phosphorylation at multiple tyrosines.  
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Figure 2.9. Importance of multi-color imaging for accurate quantification of 
phosphorylation percentages. (A) Representative images displaying raw data 
and blob-reconstructed localized molecules from a 3-color SiMPull experiment. 
CHO-EGFR-GFP cells were stimulated with 25 nM EGF for 5 min at 37°C and 
assayed using anti-pY1068-CF555 (yellow) and anti-pY1173-CF640R (pink) 
antibodies. (B) Quantification of total number of pY1068 and pY1173 
localizations per field of view when only those two channels are examined. 
EGFR-GFP channel was ignored for this quantification to emulate a 2-color 
SiMPull experiment. (C) Quantification of total number of pY1068 and pY1173 
localizations per field of view using 3-color SiMPull. Here, the EGFR-GFP 
channel was used to identify pY1068 and pY1173 localizations overlapping with 
EGFR molecules, removing contributions from non-specific antibody binding. (D) 
In the absence of the EGFR-GFP channel to identify receptor locations, the 2-
35 
 
color SiMPull underestimates protein multi-phosphorylation. Number of receptors 
per condition, N>2400. Error bars are standard error of measured 
phosphorylation percentages. 
 
2.3 Discussion 
In this Chapter, a series of modifications to SiMPull that allow this 
technique to obtain quantitative information about multiple post-translational 
modifications (PTMs) at the single-protein level were described. SiMPull was 
used to monitor EGFR phosphorylation patterns, quantify subpopulations of 
phosphorylated receptors, and directly observe the existence multisite 
phosphorylation. This approach holds distinct advantages over other techniques.  
Detailed information on protein PTMs is not accessible by traditional biochemical 
methods that can only determine relative changes from an average of the 
population.  While mass spectrometry has the potential to detect multisite 
phosphorylation, the residues of interest must be found in close proximity 
(Swaney et al., 2010).  In SiMBlot, which is also a single molecule approach to 
detecting PTMs, surface proteins are first biotinylated and then pulled-down via 
streptavidin-coated surface, rather than by a specific antibody (Kim et al., 2016). 
The SiMPull method is not restricted to surface proteins and is therefore 
compatible with the interrogation of intracellular proteins.  PTMs other than 
phosphorylation can also be studied as long as a suitable antibody is available. 
Thus, detection of PTMs by SiMPull enables measurements that were previously 
difficult to perform.   
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In addition to its advantages, SiMPull has a number of caveats that must 
be considered to ensure rigorous quantification.  As with any antibody-dependent 
technique, the affinity and specificity of the antibody must be determined.  
Results showed that it is important to establish proper concentrations and 
labeling times for each antibody used, as well as the importance of post-fixation 
to prevent antibody dissociation during imaging.  In addition, directly labeling the 
primary antibody with the fluorophore eliminates the need for secondary 
antibodies, which may add additional labeling efficiency artifacts and restrict 
options due to the limited availability of species used to generate primary 
antibodies. The phosphotyrosines probed in EGFR are located in an intrinsically 
disordered region of the C-terminal tail, therefore these sites are likely to be more 
accessible to antibodies than if they were located in structured regions. If the 
PTMs of interest are found in structured regions, a protein denaturation step may 
be used (Kim et al., 2016). Steric hindrance of two or more antibodies binding to 
the same protein is another possible complication.  Steric hindrance was found in 
the case of co-labeling pY1068 and pY1173. However, a simple control 
experiment and mathematical correction are described to avoid undercounting of 
dual-phosphorylated receptors.  For future studies, the use of fluorescently-
conjugated Fab fragments may reduce the impact of steric hindrance. It is worth 
noting that while detailed information on the phosphorylation status of individual 
proteins status is obtained, the cell-to-cell variability is lost with SiMPull.   
Using SiMPull, EGFR phosphorylation patterns were quantified. The new 
level of detail afforded by SiMPull has provided several important insights. First, 
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only a fraction of EGFR was found to be phosphorylated, even under saturating 
ligand conditions. Second, the phospho-EGFR is further divided into 
subpopulations that vary in the extent of phosphorylation at individual tyrosine 
residues.  Third, the use of three-color imaging allowed to probe for multisite 
phosphorylation.  Comparisons of pY1068 with a pan-phosphotyrosine antibody 
revealed that many receptors are indeed phosphorylated at more than one 
tyrosine simultaneously.  Strikingly, the majority of pY1068+ receptors are co-
labeled with PY antibody and ~50% of pY1068+ are also positive for pY1173. 
These results are in contrast to recent SiMBlot studies of EGFR concluding that 
multisite phosphorylation was not a common occurrence. These differences may 
be explained by optimization of our labeling protocol that provided the sensitivity 
needed to detect multisite phosphorylation, including the use of fluorescently-
conjugated primary antibodies, labeling under saturating antibody conditions and 
post-fixation to prevent antibody dissociation. 
Notably, our results are consistent with previous work indicating that 
multisite phosphorylation is important in the efficient recruitment of certain 
adaptor proteins to activated EGFR (Sigismund et al., 2013; Fortian and Sorkin, 
2014).  The existence of multisite phosphorylation holds significant functional 
implications. By modulating protein phosphorylation patterns, both single- and 
multisite combinations, downstream signaling pathways may be differentially 
activated and lead to biased signaling.  Consistent with this idea, it has been 
shown that biased signaling arises with different ligand types and doses, as well 
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as with the relative abundance of receptors and their signaling partners (Chen et 
al., 2009; Wilson et al., 2012; Freed et al., 2017; Wolf-Yadlin et al., 2006).  
Interestingly, dual Y1068/Y1173 phosphorylation occurred about two-
times more frequently than expected if these sites were independent of each 
other, suggesting positive correlation between the sites.  Mechanistically, this 
enrichment could be a result of either long-lived receptor interactions or repeated 
dimerization events.  If dimer lifetimes are sufficiently long, then phosphorylation 
of multiple sites could happen in a single dimerization event, suggesting that 
phosphorylation occurs in a semi-processive manner. Alternatively, if a receptor 
undergoes many dimerization and dissociation events, then these repeated 
interactions could result in the phosphorylation of a unique tyrosine in each 
encounter. This would be similar to quasi-processive phosphorylation as 
described for ERK (Aoki et al., 2011).  Experimental evidence exists to support 
each of these mechanisms. Both long-lived and transient EGFR dimerization has 
been observed on living cells, with dimer lifetimes dependent on ligand 
occupancy (Low-Nam et al., 2011).  Recent work from the Lemmon group has 
shown that high and low affinity ligands induce distinct dimer structures, where 
low affinity ligands lead to less stable dimers and differential signaling outcomes 
(Freed et al., 2017). Oncogenic signaling by EGFR mutants has been shown to 
be driven by enhanced dimerization and increased catalytic activity that could 
amplify multi-phosphorylation (Kim et al., 2012; Shan et al., 2012; Valley et al., 
2015; Zhang et al., 2006). 
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Interplay between receptors and the membrane environment has also 
been shown to affect the efficiency of EGFR encounters (Low-Nam et al., 2011; 
Chung et al., 2010). Therefore, the frequency of dimerization and the duration of 
dimer lifetimes may serve as a kinetic proofreading mechanism, regulating the 
EGFR phosphorylation patterns and dictating cellular outcome. Additionally, 
adaptor protein binding and phosphatase activity likely play roles in 
phosphorylation extent. For example, Capuani et al have shown that Grb2 and 
Cbl can protect Y1045/Y1068 from dephosphorylation (Sigismund et al., 2013). 
These mechanisms are not mutually exclusive and may be more or less relevant 
depending on the cellular contexts. Therefore, it would be expected that 
phospho-EGFR patterns will be modulated by differences in ligand dose, ligand-
dependent dimer lifetimes, membrane architecture and adaptor protein 
abundance. The contributions that these mechanisms have in EGFR and other 
signaling pathways, remain unclear. The unique datasets provided by SiMPull, 
combined with other experimental and computational modeling tools, should 
prove useful in addressing these types of questions. 
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2.4 Methods 
2.4.1 Cell lines and reagents 
CHO cells expressing GFP-tagged (Brock et al., 1999; Lidke et al., 2004) 
or ACP-tagged EGFR (provided by Dr. Donna Arndt-Jovin) were cultured in 
DMEM supplemented with 10% FBS, penicillin–streptomycin and 2 mM L-
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glutamine (Thermo Fisher Scientific). ACP-tagged EGFR was as described in 
(Valley et al., 2015; Ziomkiewicz et al., 2013) with the exception that a shortened 
16 aa sequence was introduced at the EGFR N-terminus (George, 2006). EGF, 
Protease and Phosphatase Inhibitor Cocktail, Alexa Fluor 647 NHS Ester, and 
NeutrAvidin were purchased from Thermo Fisher Scientific. CoA 488 and ACP 
Synthase were purchased from New England Biolabs. N-(2-aminoethyl)-3-
aminopropyltrimethoxysilane was purchased from United Chemical Technologies 
(#A0700). Sodium bicarbonate and sodium borohydride were purchased from 
EMD Millipore (#SX0320-1, #SX0380-3). mPEG-Succinimidyl Valerate (MPEG-
SVA-5000-5g) and biotin-PEG-Succinimidyl Valerate (Biotin-PEG-SVA-5000-
500mg) were from Laysan Bio. Biotinylated anti-EGFR antibody (E101) was 
obtained from Leinco Technologies. Antibodies in carrier-free buffer were 
purchased from Cell Signaling Technologies:  EGFR pY1068 (clone 1H12, 
2236BF) and EGFR pY1173 (clone 53A5, 4407BF). Monoclonal antibody pre-
labeled with AF647 to detect pan-tyrosine phosphorylation (PY99 antibody, sc-
7020 AF647) was purchased from Santa Cruz Biotechnology. Mix-n-Stain CF555 
and CF640R antibody labeling kits were purchased from Biotium Inc. 
Paraformaldehyde and glutaraldehyde were purchased from Electron Microscopy 
Sciences. 
  
2.4.2 Labeling of antibodies 
Carrier-free antibodies (50 μg at 0.5-1 mg/mL per reaction) were labeled 
using Mix-n-Stain antibody labeling kits following the manufacturer’s instructions. 
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Briefly, the labeling reaction was carried out for 30 min at room temperature and 
antibodies were centrifuged using the ultrafiltration vial provided to remove the 
unconjugated dye. Antibodies were resuspended in PBS and stored at 4 °C. The 
labeling efficiency achieved was between 2.7-4.4 dyes/antibody.  
 
2.4.3 Cell treatment and lysate preparation 
CHO-EGFR-GFP cells were plated overnight in 60 mm tissue culture 
dishes at 800,000 cells/dish and CHO-ACP-EGFR cells in 24-well plates at 
50,000 cells/well. For ACP labeling, CHO-ACP-EGFR cells were washed with 
serum-free DMEM medium (SFM), incubated with ACP labeling solution (SFM, 
10 mM MgCl2, 4 μM CoA 488 and 1 μM ACP) for 20 minutes at 37°C and 
washed three times with SFM previous to stimulation. Cells were washed in 
Tyrode’s solution (135 mM NaCl, 10 mM KCl, 0.4 mM MgCl2, 1 mM CaCl2, 10 
mM HEPES, 20 mM glucose, 0.1% BSA, pH 7.2) and treated with 25 nM EGF or 
Tyrode’s solution alone (resting cells) at 37°C. At the indicated time points,  cells 
were placed on ice, washed one time with cold PBS followed by addition of lysis 
buffer (1% IGEPAL CA-630, 150 mM NaCl, 50 mM Tris pH 7.2) containing 
Protease and Phosphatase Inhibitors. Cell lysates were collected using cell 
scrapers (Greiner Bio-One North America, #541070), transferred to fresh tubes 
on ice and vortexed every 5 min for a total of 20 min. Lysates were centrifuged at 
16,000× g for 20 min at 4 °C and the supernatant was transferred to a new tube 
and stored at -80 °C. For experiments involving treatment of cells with 
phosphatase inhibitors, cells were pre-treated for 15 min with a Tyrode’s solution 
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containing 1 mM pervanadate (PV) followed by incubation for 5 min in a solution 
with 50 nM EGF and 1 mM PV. A stock solution of 30 mM PV was prepared 
before each experiment by mixing equimolar concentrations of hydrogen 
peroxide and activated sodium orthovanadate that was incubated in the dark for 
at least 15 min before use. 
 
2.4.4 Fabrication of hydrophobic arrays and surface functionalization 
Coverglasses (24x60mm, #1.5; Electron Microscopy Sciences, #63793) 
were Piranha-cleaned(Labit et al., 2008) and placed in a coverglass holder 
(Fisher Scientific, #08-817). Coverglasses were sequentially sonicated in 
Methanol and Acetone for 10 min each, and in 1M KOH for 20 min using a bath 
sonicator (Branson Ultrasonics, B1200R-1). These solutions were stored in 
polypropylene 50 mL tubes (VWR, #89401-564) and reused up to five times. 
Coverglasses were rinsed with Milli-Q water two times, dried by quickly passing 
them multiple times over the flame of a Bunsen burner using metal tweezers and 
placed in a dry coverglass holder. A solution containing 76 mL of methanol, 4 mL 
of acetic acid and 0.8 mL of aminosilane (N-(2-aminoethyl)-3-
aminopropyltrimethoxysilane) was prepared in an Erlenmeyer flask, immediately 
poured into the coverglass holder and incubated at room temperature for 10 min 
in the dark, followed by  2 min sonication and another 10 min incubation in the 
dark. Coverglasses were next washed with methanol for 2 min, rinsed and 
washed for 2 min with water, and dried in the dark. 
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Treated coverglasses were placed on top of a parafilm-covered 
coverglass containing a guide pattern, which was used as reference to draw the 
Sample Array with a hydrophobic barrier pen (Vector Laboratories, #H-4000). Ink 
was allowed to dry for at least 5 min before coverglasses were placed in a 
humidified chamber (empty tip rack with 50 mL of water; USA Scientific #1111-
2820). For surface functionalization, 50 mg of mPEG-Succinimidyl Valerate, 1.3 
mg of biotin-PEG-Succinimidyl Valerate and 200 µL of freshly prepared 10 mM 
sodium bicarbonate were mixed thoroughly by pipetting up and down, centrifuged 
for 1 min at 10,000 g at room temperature and immediately applied to the 
SiMPull array (10-13 uL per region). After incubating for 3-4 hours in the dark 
inside the humidified boxes, arrays were washed by sequential 30 sec 
submersions into three water-filled 250 mL glass beakers. Coverglasses were 
dried with nitrogen gas, stored in pairs (back to back) inside 50 mL tubes, which 
were filled with nitrogen gas before closing and sealing with Parafilm. 
Coverglasses were stored in the dark at -20°C for up to a week before use.  
 
2.4.5 Labeling and quantification of surface receptors 
CHO-EGFR-GFP cells grown in 24-well plates were placed on ice and 
washed 3 times with cold PBS. AF647-NHS Ester was dissolved at the indicated 
concentrations in PBS. Cells were incubated with this solution for 30 min at 4°C 
with gentle agitation, washed 3 times with cold PBS and subjected to cell lysis. 
The percent of receptors labeled with AF647 across different dye concentrations 
was assessed with SiMPull.  To estimate the percent of receptors at the cell 
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surface the AF647-labeling curve was fitted to a biexponential decay curve in its 
increasing form using the ‘fit’ function in MATLAB: y = C1 (1 - e-ax) + C2 (1 - e-bx), 
where y is the % of AF647-labeled receptors, x is the concentration of reactive 
AF647-NHS ester used, and a>0, b>0, C1 and C2 are coefficients to be fitted. 
The sum of the coefficients C1 and C2 represent the asymptote of the curve and 
an approximation of the fraction of receptors at the cell surface. 
 
2.4.6 Single-Molecule Pulldown and phospho-site labeling 
T50 (10 mM Tris pH 8.0, 50 mM NaCl) and T50-BSA (T50 with 0.1 mg/mL 
BSA) solutions were prepared and stored for up to a month at room temperature. 
SiMPull arrays were equilibrated at room temperature and placed on a TC100 
plate lined with Parafilm. Each region of the SiMPull array was treated with 10-15 
µL of a 10 mg/mL sodium borohydride (NaBH4)/PBS solution for 4 min at room 
temperature and washed 3 times with PBS. SiMPull regions were then incubated 
with a 0.2 mg/mL NeutrAvidin/T50 solution for 5 min and washed three times with 
T50, followed by incubation with a 2 µg/mL biotinylated anti-EGFR/T50-BSA 
solution for 10 min and washed three times with T50-BSA.  
The plate containing the SiMPull array(s) was kept on ice during sample 
preparation. Lysates were diluted in cold T50-BSA with Protease and 
Phosphatase Inhibitors (T50-BSA/PPI), vortexed at medium speed, and added to 
the SiMPull array. After 10 min incubation, the lysates were removed and the 
SiMPull regions washed 4 times with cold T50-BSA/PPI. To determine 
appropriate dilution factor, the density of pulldown receptors as a function of 
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lysate concentration was first assessed to achieve a pulldown density 0.04-
0.08/μm2. Antibodies were diluted in cold T50-BSA/PPI, incubated for 1 hr, 
washed 6 times with cold T50-BSA for a total of 6-8 minutes, and washed twice 
with cold PBS. Immediately after, antibodies were fixed for 10 min with a 4% 
PFA/0.1% GA solution (paraformaldehyde/glutaraldehyde) and washed 2 times 
with 10 mM Tris (pH 7.4)/PBS for a total of 10 min to inactivate fixatives.  For 3-
color SiMPull experiments the same antibody incubation and fixation procedure 
was performed for the second antibody. Tris solution was replaced by T50-BSA 
and the SiMPull array was equilibrated to room temperature before proceeding to 
imaging. 
 
2.4.7 SiMPull imaging 
Imaging of SiMPull samples was performed using an inverted microscope 
(Olympus America, model IX71) equipped with a 150×/1.45 NA oil-immersion 
objective for Total Internal Reflection Fluorescence Microscopy (Olympus 
America, UAPON 150XOTIRF) and a three-dimensional piezostage (Mad City 
Labs, Nano-LPS100). Excitation of CF640R- or AF647-labeled antibodies was 
done using a 642-nm laser (Thorlabs, HL63133DG), CF555-labeled antibodies 
using a 561-nm laser (Coherent Inc, Sapphire 561-100 CW CDRH), and of GFP- 
and CoA 488-tagged receptors using a 488-nm laser (Spectra Physics, Cyan 
100mW). All lasers were set in total internal reflection configuration, and laser 
powers were adjusted to prevent photobleaching of the sample at the timescale 
of the image exposure time (300 msec). Sample illumination and emission were 
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filtered using a quad-band dichroic and emission filter set (Semrock, 
LF405/488/561/635-A-000). Emission light was separated into four channels 
using a quad-view multichannel imaging system (Photometrics, model QV2) 
equipped with the appropriate dichroics (Chroma, 495 DCLP, 565 DCLP, 660 
DCLP) and emission filters (Semrock, 685/40 nm, 600/37 nm, 525/45 nm). 
Emission light was collected with an electron-multiplying charge-coupled device 
(EMCCD) camera (Andor Technology, DU-897E-C50-#BV) with EM gain set to 
200. 
Each channel was 256 x 256 pixels, with a pixel size of 106.7 nm. 
Photobleaching and bleed through were prevented by controlling the laser 
shutters and microscope stage through a MATLAB script to sequentially excite 
and acquire the different fluorophores (642-nm laser first, 488-nm laser last). A 
minimum of 20 regions of interest were acquired per condition. For quantification 
of step photobleaching of EGFR-GFP molecules, a 100 frame time series (300 
msec exposure time) was acquired after imaging of the other two channels. 
 
2.4.8 Quantification of Receptor Phosphorylation 
All image processing was performed using MATLAB together with the 
MATLAB toolbox for image-processing DIPImage (Delft University of 
Technology) (Hendriks et al., 1999) and all software is available upon request. 
The location of emitters in each channel was calculated using graphics processor 
unit (GPU) computing as previously described (Smith et al., 2010). Fits in the 
GFP channel were filtered based on the quality of the fit to the point spread 
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function to reduce the chances of detecting multiple receptors in close proximity 
as a single molecule. Image registration was performed as previously described 
(Schwartz et al., 2017). In this work, the root mean square error for image 
registration was <10 nm. For visualization purposes, Gaussian blob 
representations of the fluorophore localizations were generated. A receptor was 
considered to be phosphorylated when the localization centers of the receptor 
and labeled antibody were at a distance <106.7 nm (within 1 pixel). 
Phosphorylation percentages were calculated as 100*(NPhos)/(NGFP-NBG) 
where NPhos is the number of receptors identified as phosphorylated, NGFP is the 
number of observed single molecules in the GFP channel and NBG is the non-
specific background rate in the GFP channel.  
The number of GFP localizations was calculated by subtracting 
background spots and accounting only for surface receptors as follows: NGFP = 
(NLOC-NBG )*SR, where NLOC is the total number of emitters localized, NBG is the 
expected number of background emitters in the area imaged, and SR (surface 
ratio) is the fraction of receptors located at the cell surface. The density of 
background emitters was quantified for each SiMPull array and used for 
background correction of samples in that array. For 3-color SiMPull experiments 
where steric hindrance between sequentially incubated antibodies was observed 
(i.e. pY1068-pY1173 detection), estimations of dual phosphorylation were 
corrected to account for this hindrance as explained in Figure 2.7. 
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2.4.9 Statistical Analysis 
Based on the consideration that the phosphorylation state of each 
receptor analyzed has the properties of a Bernoulli trial, standard errors (SE) of 
phosphorylation measurements were calculated as for sample proportions in a 
binomial distribution: SE= p(1-p)/n, where p is the fraction of receptors 
phosphorylated and n is the total number of receptors. The condition np>10 (with 
the exception of Figure 2.8E, np>5) and np(1-p)>10 was ensured to be met to 
allow this approximation to be adequate. Two-sample Z-test (two-tailed) was 
used to estimate p-values (LeBlanc, 2004).  
 
2.4.10 Step-photobleaching Analysis 
For step-photobleaching analysis of multi-phosphorylated receptors, the 
average fluorescence intensity of the area (200x200 nm) surrounding each of 
these EGFR-GFP molecules was quantified and plotted for the duration of the 
time series. Intensity plots were manually analyzed and the number of 
photobleaching steps was quantified. For a small fraction of the emitters, the 
number of molecules could not be reliably counted because either they 
photobleached too quickly (<2 frames) or did not photobleach during the duration 
of the movie, and therefore were excluded from the analysis. 
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Chapter 3 : Building a rule-based model of the initial events of 
EGFR signaling 
 
3.1 Introduction 
A number of rule-based models for EGFR signaling have been developed 
in recent years, each varying in complexity and the level of mechanistic details 
included (Blinov et al., 2006; Creamer et al., 2012; Kozer et al., 2013b). The 
refinement of these models was mostly done using techniques that provide 
ensemble or average quantitative measurements. The kind of information that 
the improved SiMPull technique (described in Chapter 2) provides was not 
available in the past, and therefore this model will be the first one whose 
refinement is performed using this type of data. As described in following 
chapters, coupling of this type of modeling and experimental data is providing 
new insights about the kinetics of the molecular events involved in EGFR 
activation. 
The following sections present a detailed description of the development 
of a model that simulate the EGF-dependent activation of EGFR, phosphorylation 
of tyrosines 1068 and 1173 in the cytoplasmic tail of the receptor and the 
recruitment of adaptor proteins Grb2 and Shc1 to these sites (Figure 3.1). This 
model was developed using the BioNetGen language (BNGL) for rule-based 
modeling (Faeder et al., 2009). The model consists of 9 reaction rules and 12 
parameters. BioNetGen software was used to generate the reaction network from 
these rules. The resulting reaction network consists of 39 molecular species and 
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183 unidirectional reactions. The network was simulated with the deterministic 
simulation engine used by BioNetGen. 
In the next section, two example rules are presented to briefly describe the 
basic nomenclature in BioNetGen language. A more detailed description of 
BioNetGen language can be found in (Faeder et al., 2009). This is followed by a 
list of the reaction rules used for this model together with a brief description. 
Lastly, some of the key parameter values used in this model are enlisted, and the 
source(s) of these values, if available. A complete list of the parameter values 
and the file encoding the complete model can be found in Appendix B. 
 
 
Figure 3.1. Graphical description of model. EGF-bound receptors can dimerize 
and phosphorylated each other. This model includes the phosphorylation of 
Y1068 and Y1173, and the recruitment of Grb2 and Shc1 to those respective 
sites. 
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3.2 Model development, Results and Discussion 
3.2.1 Example reaction rules 
Example Rule 1. Reversible interaction between A and B 
A(domA)+B(domB)<->A(domA!1).B(domB!1) kp,km 
The proteins ‘A’ and ‘B’ can interact through their domains ‘domA’ and ‘domB’, 
and form a complex. Components of a complex are separated by a dot and the 
molecular bonds are indicated with a ‘!’ sign and a number. For example, if more 
than one molecular bond is present in a molecular complex then the bonds would 
be labeled as ‘!1’, ‘!2’, ‘!3’, and so on. Note that ‘domA’ and ‘domB’ in the 
reactants side do not have a ‘!’, which means that they have to be free or 
unbound in order for the association reaction to occur. The forward (‘kp’ or k+) 
and reverse (‘km’ or k-) reaction rates are indicated after the rule and separated 
by a comma. For unidirectional reactions, only one reaction rate is specified. 
Example Rule 2. Phosphorylation of protein A when it is bound (to protein B) 
A(domA!+,Y1~0)->(domA!+,Y1~P) kp 
Phosphorylation of ‘Y1’ can only happen if its domain ‘domA’ is bound to other 
protein (‘domA!+’). In this case, protein ‘B’ can be thought as a kinase that 
phosphorylates protein ‘A’ in ‘Y1’. The expression ‘!+’ in ‘domA!+’ indicates that 
‘domA’ needs to be bound, regardless of to which protein it is bound to. 
Alternatively, the whole complex can be explicitly specified as indicated below: 
 A(domA!1,Y1~0).B(domB!1)-> A(domA!1,Y1~P).B(domB!1) kp 
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Only domains that are relevant to the reaction are included. For example, in the 
first example rule the site ‘Y1’ was not included, because the interaction happens 
regardless of the state of ‘Y1’. BioNetGen software will generate a reaction for 
each possible molecular species. 
 
3.2.2 Reaction rules 
R1. EGF reversibly binds EGFR 
EGF(EGFL)+EGFR(I_III)<->EGF(EGFL!1).EGFR(I_III!1) kp_EGF,km_EGF 
In this simple rule EGF binds to domains I and III on EGFR with a rate ‘kp_EGF’, 
and dissociates with a rate ‘km_EGF’. 
R2. Dimerization of EGF-bound receptors 
EGFR(I_III!+,II~u)+EGFR(I_III!+,II~u)-> 
EGFR(I_III!+,II~b)+EGFR(I_III!+,II~b) kp_dim_L_L 
EGFR that is bound to EGF (‘I_III’ domain occupied) and that has its dimerizing 
domain ‘II’ unbound (‘II~u’) can dimerize with another receptor of the same kind. 
The dimerization event changes the state of domain II from unbound to bound 
(II~u->II~b), which is an implicit way of representing dimerization. Originally the 
dimerization event was described explicitly, meaning that the two receptors 
actually formed a complex. Comparing simulation results from the models that 
considered dimerization implicitly and explicitly, both models behaved almost 
identically (not shown), although the model with explicit dimerization had a much 
higher number of molecular species and reactions. This reduced complexity of 
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the implicit dimers is because they have the same number of components as a 
monomer, while in explicit dimers there are twice as many components as in a 
monomer.  Considering that complexity increases non-linearly with the number of 
components of a molecule, explicit dimers have many more possible states that 
implicit dimers (for the current model a factor of 7 increase). This increase in 
complexity becomes relevant when fitting the model to experimental results, 
which could take days or even weeks.  
Alternative versions tested: Dimerization between unliganded-unliganded or 
liganded-unliganded receptors was initially considered. In this model transition of 
EGFR ectodomain between tethered and extended conformations was 
considered implicitly by defining a parameter that defined the probability of 
receptors to be in an extended conformation (dimerization competent).   
Comparing simulation results with the model that only allowed two EGF-bound 
receptors to dimerize showed that they behaved very similar, and that only varied 
slightly at low EGF doses (not shown). Therefore, the model was simplified and 
only allow two EGF-bound receptors to form dimers. If the model is intended to 
be used for studying processes at low EGF doses, like ERK activation at sub-
nanomolar EGF concentrations, then it may be necessary to add these rules 
back into the model. 
R3. Dissociation of EGFR dimer 
EGFR(II~b)->EGFR(II~u) km_dim_L_L 
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Similarly to EGFR dimerization, dissociation of EGFR dimers was considered 
implicitly, giving equal results as when considered explicitly. The dissociation 
event changes the state of domain II from bound to unbound (II~b->II~u). 
 
R4 and R5. EGFR autophosphorylation 
EGFR(II~b,Y1068~0)->EGFR(II~b,Y1068~P) kphos1068 
EGFR(II~b,Y1173~0)->EGFR(II~b,Y1173~P) kphos1173 
Receptors that are in a dimer (II~b) can be phosphorylated with rate ‘kphos’. The 
state of the tyrosine residue changes from unphosphorylated to phosphorylated 
(Y~0->Y~P).  
Asymmetric arrangement of the kinase domains in an EGFR dimer was not 
considered for the results presented in this dissertation, but an updated version 
of the model including asymmetric phosphorylation have just been created, and 
will be used for the peer-reviewed publication of this work. Although the 
parameters for phosphorylation rate needed to be modified for this updated 
model, the simulation results from this model are very similar to the ones 
obtained with the model used for this dissertation. 
R6 and R7. Dephosphorylation of pY sites 
EGFR(Y1068~P)->EGFR(Y1068~0) kdephos1068 
EGFR(Y1173~P)->EGFR(Y1173~0) kdephos1173 
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Sites that are phosphorylated (Y~P) and unbound (absence of ‘!+’ sign) can be 
dephosphorylated with a rate ‘kdephos’. Dephosphorylation is considered 
implicitly as being constitutively active (constant dephosphorylation rate). 
R8. Binding of Grb2 to pY1068 
GRB2(SH2)+EGFR(Y1068~P)<-> GRB2(SH2!1).EGFR(Y1068~P!1) 
kp_GE,km_GE 
The SH2 domain from Grb2 binds to phosphorylated tyrosine 1068 in EGFR. 
Both domains/sites must be free in order to bind. 
Even though Grb2 can also bind directly to other sites, like pY1086, or indirectly 
through Shc1, these interactions were not considered in this model. 
R9. Binding of Shc1 to pY1173 
SHC1(PTB)+EGFR(Y1173~P)<-> SHC1(PTB!1).EGFR(Y1173~P!1) 
kp_SE,km_SE 
The PTB domain from Shc1 binds to phosphorylated Y1173 in EGFR. 
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3.2.3 Model parameters 
Model parameters presented here were subsequently transformed to units of 
molecules/cell and to units of seconds.  
Avogadro constant (NA) 
Value: 6.02214 x1023 /mol 
Used to convert concentrations in molarity to concentrations in molecules per 
cell. 
Cytoplasmic volume (Vc) 
Value: 1 picoliter 
Source: Cytoplasmic volume estimated by Fujioka et al. for HeLa cells (Fujioka et 
al., 2006). 
Grb2 and Shc1 concentration (GRB2_total and SHC1_total) 
Value: 1.0x104 - 1.0x106 copies/cell 
Source: Abundance of these proteins was allowed to vary in the range specified 
above for the fitting process. Naïve model was set to have values of 1.0x105 for 
both proteins. 
Number of EGFR (EGFR_total) 
Value: 6.0x105 receptors/cell 
Source: Value estimated previously in our laboratory for CHO EGFR-GFP cells 
using flow cytometry. 
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Association rate for cytoplasmic interactions (kon) 
Value: 5.0x106 /M/s 
Source: Assumed to be 5.0x106 /M/s for all interactions occurring at the 
cytoplasm (including receptor-adaptor protein interactions). 
Association rate for EGF-EGFR interaction (kon_EGF) 
Value: 8.0x106 /M/s 
Source: This rate was set to this value so that EGFR phosphorylation kinetics 
occurs similarly to kinetics measured at high temporal resolution using mass 
spectrometry (Reddy et al., 2016). 
Dissociation constant (Kd) for EGF-EGFR interaction (Kd_EGF) 
Value: 1 nanomolar (1.0x10-9 M) 
Source: A dissociation constant of 1 nM was used for this interaction, which it is 
close to previously estimated values (Björkelund et al., 2011). Dissociation rate 
for this interaction was obtained using the values for kon_EGF and Kd_EGF. 
Dissociation rate for EGF-bound EGFR dimers (Vc) 
Value: 0.273/s 
Source: Dissociation rate estimated in A431 cells by Low-Nam et al. using Single 
Particle Tracking (Low-Nam et al., 2011). 
Dissociation constant (Kd) for EGF-bound EGFR dimers (KD_dim) 
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Value: 60,000 molecules/cell 
Source: This parameter was set so that EGFR_total/KD_dim >> 1. 
Dissociation constant (Kd) for Grb2-pY1068 EGFR interaction (Kd_GE) 
Value: 600 nM 
Source: As estimated by Morimatsu et al. using single-molecule microscopy 
(Morimatsu, M., Takagi, H., Ota, K. G., Iwamoto, R., Yanagida, T., & Sako, 
2007). 
Dissociation constant (Kd) for Shc1-pY1173 EGFR interacton (Kd_SE) 
Value: 600 nM 
Source: Assumed to be the same as for Grb2-pY1068. This assumption was 
based on affinity measurements for protein domains binding to phospho-peptides 
of these sites showing similar affinities for Grb2-pY1068 and Shc1-pY1173 
interactions (Kaushansky et al., 2008; Hause et al., 2012). 
Phosphorylation and dephosphorylation rates (kphos and kdephos) 
Value: 0.5-5.0 /s 
Source: Allowed to vary in this range. Congruent with rates estimated by 
(Kleiman et al., 2011). 
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Chapter 4 : Insights on EGFR signaling by integrating 
computational modeling and single molecule data  
 
4.1 Introduction 
This Chapter focuses on the integration between the experimental and 
computational modeling tools developed in Chapters 2 and 3. Chapter 2 
describes a series of modifications to the Single Molecule Pull-down (SiMPull) 
technique to quantify the fraction of site-specific phosphorylation in EGFR. Then, 
Chapter 3 describes the development of a rule-based model for EGFR signaling. 
Building on those developments, SiMPull data was used to refine the rule-based 
model, and vice versa, the rule-based model was used to generate predictions 
that can be tested experimentally. The overall goal of this experiment-modeling 
integration is to gain a quantitative understanding of the dynamic behavior of the 
different processes involved in signaling. 
One particular observation that the model could not initially reproduce was 
the differential phosphorylation in tyrosine 1068 and 1173 of EGFR. In these 
results, Y1173 consistently had higher phosphorylation levels than Y1068 at 
different EGF doses and times of stimulation (see Figure 2.5 in Chapter 2). To 
explore the possible origins of this behavior the rule-based model was used. The 
model suggested that adaptor proteins are able to protect the phospho-sites to 
which they bind from dephosphorylation, and that differences in adaptor protein 
abundances could give rise to differential phosphorylation. Particularly, the model 
predicted that an increase in the abundance of Grb2 would result in a higher 
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percentage of receptors phosphorylated at sites to which Grb2 binds. In 
agreement with this prediction, overexpression of Grb2 caused a dramatic 
increase in the phosphorylation levels of a Grb2-binding site in EGFR (Y1068), 
but not in a site which Grb2 does not bind (Y1173). Preliminary results suggest 
that these observations using protein overexpression may translate to cells 
naturally expressing different levels of adaptor proteins. Results show that 
adaptor protein abundances are able to alter the phosphorylation levels of their 
binding partners resulting in biased phosphorylation in vivo.  
 
4.2 Results 
4.2.1 Model can fit experimental data with only allowing adaptor protein 
abundances to vary 
In the previous chapter, a model of EGFR signaling was described, and 
while many of the parameter values have been estimated experimentally, some 
others have not. Also, it is important to consider that measurements are 
approximations of the actual values and that these values likely change between 
different conditions, including in which cell type the measurements were 
performed. Therefore, the model parameters need to be adjusted to allow the 
model to be able to reproduce experimental data. Simulation results from the 
unmodified or naïve model show similar levels of phosphorylated tyrosine 1068 
and 1173 (pY1068 and pY1173), while the experimental data suggests that 
phosphorylation at Y1173 is higher than for Y1068 (Figure 4.1). 
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Figure 4.1. Comparison of naïve model and experimental data. Percentages of 
EGFR phosphorylation at tyrosines 1068 (a) and 1173 (b) after stimulation with 
25 nM of EGF obtained experimentally using SiMPull (blue) or predicted by the 
naïve model (red). Error bars represent mean +/- S.E.M. 
 
There are different parameter values that can be adjusted to reproduce 
the biased phosphorylation observed experimentally. Probably the most obvious 
one would be to allow the phosphorylation rate in one site (Y1173) to be higher 
than in the other. Another possibility is to have different dephosphorylation rates 
for each site. Phosphorylation rates measured in vitro as well as 
dephosphorylation rates measured in vivo were very similar for both sites, and 
therefore could not account for the biased phosphorylation observed in our 
experiments (Kim et al., 2012; Kleiman et al., 2011). A third and less obvious 
possibility would be to allow the abundance of the adaptor proteins (i.e. Grb2 and 
Shc1) to vary. The reason changes in adaptor protein abundances affect 
phosphorylation levels in the model is because an adaptor protein bound to the 
phosphorylated site protects the site from dephosphorylation by means of steric 
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hindrance (Figure 4.2a). This hypothesis is supported by in vitro studies showing 
the ability of SH2 domains to protect phospho-sites from dephosphorylation 
(Rotin et al., 1992; Brunati et al., 1998). To test if variation in protein abundances 
alone could explain the data, abundances of Grb2 and Shc1 were allowed to 
differentially vary during the fitting process, while phosphorylation and 
dephosphorylation were varied equally for both sites. The ability of the model to 
match the experimental results based on differential abundance of adaptor 
proteins supports the feasibility of this mechanism being responsible for the 
biased phosphorylation observed (Figure 4.2b,c). 
 
 
Figure 4.2. Fitting model to experimental data by varying adaptor protein 
abundances. (a) Graphical representation of mechanism of protection of 
phosphorylated sites from phosphatases by adaptor proteins. Percentages of 
EGFR phosphorylation at tyrosines 1068 (b) and 1173 (c) after stimulation with 
25 nM of EGF obtained experimentally using SiMPull (blue) or predicted by the 
fitted model (red). Error bars represent mean +/- S.E.M. 
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4.2.2 Predicted influence of Grb2 overexpression in phosphorylation levels 
is observed experimentally 
The fact that the model is able to simulate biased phosphorylation by 
having different values for the abundances in Grb2 and Shc1 does not supports 
the hypothesis that adaptor proteins are able to modulate phosphorylation levels. 
Therefore, a series of predictions of the expected effect that overexpression of 
Grb2 would have on the phosphorylation levels of the two sites were generated. 
The model predicts that Grb2 overexpression will lead to increased 
phosphorylation at Y1068, where Grb2 binds, and no change in phosphorylated 
Y1173, where Grb2 is not expected to bind (Figure 4.3a,b). To test this 
prediction, human Grb2-mCherry was overexpressed and its effect on EGFR 
phosphorylation was quantified. Consistent with model predictions, 
overexpressing Grb2 lead to a marked increase in the phosphorylation of Y1068, 
but only a slight increase in the phosphorylation of Y1173 (Figure 4.3c,d). 
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Figure 4.3. Predicted and observed phosphorylation kinetics in cells 
overexpressing Grb2. Predicted percentages of EGFR phosphorylation at 
tyrosines 1068 (a) and 1173 (b) after stimulation with 25 nM of EGF in cells with 
increasing overexpression (OE) of Grb2. Percentages of EGFR phosphorylation 
at tyrosines 1068 (c) and 1173 (d) after stimulation with 25 nM of EGF in cells 
expressing endogenous levels of Grb2 (orange, CHO ErbB1-GFP) or 
overexpressing Grb2-mCherry (blue). Measurements were done using SiMPull. 
Error bars represent mean +/- S.E.M. 
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4.2.3 Model predicts cell-specific phosphorylation patterns based on 
differences in adaptor protein abundances 
Considering the observed ability of adaptor protein overexpression to 
affect the levels of EGFR phosphorylation in a site-specific manner, it can be 
hypothesized that cell types that naturally express different levels of these 
adaptor proteins would display different phosphorylation patterns. Using global 
and targeted proteomics two research groups recently obtained estimates for the 
abundance of different proteins in different normal and cancer cell lines (Shi et 
al., 2016; Kulak et al., 2014). These estimates include the protein copy numbers 
(per cell) for EGFR, Grb2 and Shc1 in the non-tumorigenic mammary epithelial 
HMEC and MCF10A cells, and in the cervical cancer HeLa cells (Figure 4.4a). 
Simulations were performed using these values and model predictions for the 
phosphorylation patterns/kinetics in these three cell lines were obtained (Figure 
4.4b-d). In the HMEC cells, where the estimated abundances of both adaptor 
proteins are relatively low, the model predicts similar levels of phosphorylation at 
both tyrosine residues. For the MCF10A cells, the model predicts slightly higher 
phosphorylation at Y1173 given that its binding partner Shc1 is expressed in 
higher amounts than Grb2. The most evident difference in expression levels is 
found in HeLa cells, where it is estimated that there are ~600,000 molecules of 
Grb2 per cell, compared to ~100,000 molecules of Shc1 per cell. The model 
predicts that phosphorylation at Y1068 would be ~1.45 times higher than at 
Y1173 (Figure 4.4d). This prediction was tested experimentally in HeLa S3 cells, 
where phosphorylation at Y1068 was higher than at Y1173, in agreement with 
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the model prediction (Figure 4.4e). The difference in phosphorylation of these 
two sites was lower than what the model predicted, with Y1068 being ~1.11 times 
more phosphorylated than Y1173, compared to ~1.45 times higher pY1068 
predicted by the model.  
 
 
Figure 4.4. Phosphorylation patterns predicted for different cell types and 
observed for HeLa S3 cells. (a) Estimation of protein copy numbers for different 
cell lines estimated by Shi et al. (2016) and Kulak et al. (2014). (b-d) Predictions 
of phosphorylation kinetics for different cell lines. (e) Phosphorylation pattern in 
HeLa S3 cells obtained with SiMPull. Error bars represent mean +/- S.E.M. 
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4.3 Discussion 
Using computational modeling and Single-molecule Pulldown, the ability of 
adaptor proteins to protect phospho-sites from dephosphorylation and alter 
phosphorylation levels in vivo was shown. As predicted by the model, it was 
shown that overexpression of the adaptor protein Grb2 leads to increased 
phosphorylation of an EGFR tyrosine residue where Grb2 binds (Y1068), while a 
site where Grb2 does not strongly bind is minimally affected (Figure 4.3). The 
model predicted different phosphorylation patterns for cell lines in which protein 
abundances were previously estimated (Figure 4.4) (Shi et al., 2016). For 
example, the model predicted that the cervical cancer HeLa S3 cells, which 
express ~6 times more Grb2 than Shc1, would have higher phosphorylation 
levels at the Grb2-binding site Y1068 than at the Shc1-binding site Y1173. 
Experimental testing of this prediction with SiMPull showed that phosphorylation 
levels are indeed higher at Y1068 than at Y1173. Nevertheless, the difference in 
phosphorylation between these sites was not as high as predicted by the model. 
The ability of protein domains to protect the phosphorylated residues to 
which they bind from dephosphorylation has been demonstrated in vitro (Rotin et 
al., 1992; Batzer et al., 1994; Brunati et al., 1998). Even though this protection 
can happen in the conditions of in vitro experiments, in which high concentrations 
of the reactants are generally used, less is known about the relevance of this 
phospho-site protection in the context of living cells. A similar study was recently 
published (Jadwin et al., 2018). In this work, they studied the quantitative relation 
between Grb2 overexpression and enhancement of site-specific EGFR 
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phosphorylation (7 sites analyzed) obtaining similar results to the ones presented 
here. The evidence for the relevance of phospho-site protection at physiological 
Grb2 expression levels presented in this dissertation should be useful information 
additional to the one contributed by Jadwin et al. Also, while their computational 
model collapse all the tyrosine residues into one global tyrosine, our rule-based 
model has site-specific phosphorylation resolution. 
The phosphorylation at Y1068 increased ~2-fold when Grb2 was 
overexpressed, but little change was observed in a site where Grb2 is not known 
to bind. These results support the idea that adaptor proteins are able to affect 
phosphorylation levels of the sites to which they bind.  In order to get a better 
idea of the quantitative relation between Grb2 levels and protection of phospho-
sites, the concentration of Grb2 in these cells will be measured. 
As mentioned before, the model predicted that HeLa S3 cells would be 
~1.45 times more phosphorylated at Y1068 than at Y1173, due to its high Grb2 
expression levels. Quantification of phosphorylation levels using SiMPull showed 
that Y1068 phosphorylation was only ~1.11 times higher than Y1173 
phosphorylation. This discrepancy may be explained by technical limitations in 
the quantification of protein abundances or phosphorylation levels, however there 
are other possible explanations.  
It is possible that the ability of Grb2 to protect Y1068 from 
dephosphorylation is being overestimated, or the ability of Shc1 to protect Y1173 
underestimated, or a combination of both. Also it is important to notice that 
phosphorylation levels in HeLa S3 cells are higher than in CHO cells, even when 
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expression levels of EGFR are expected to be lower in HeLa cells. A possible 
explanation for this could be that phosphatase activity is lower in these cells, in 
which case protection by adaptor proteins would be less apparent. To distinguish 
these possibilities, the phosphorylation patterns on CRISPR-engineered HeLa S3 
clones lacking one or two of the copies of Grb2 or Shc1 will be measured. The 
level of decrease in Grb2 and Shc1 expression of these clones will be quantified 
using WB. These measurements together with the computational model will 
provide with valuable quantitative information about the effect that variations in 
adaptor protein abundances have on phosphorylation levels. This information 
could in turn be used in combination with other experiments to explore the 
relevance of this protection in downstream signaling. This may be of special 
relevance in cancer cells, which often have aberrant expression levels of adaptor 
proteins. 
Even though the focus of this study is on the adaptor proteins Grb2 and 
Shc1, these observations likely translate to other proteins binding to post-
translationally modified sites. Proteins with interaction lifetimes longer than those 
of Grb2 and Shc1 may protect their binding sites with a higher efficiency than that 
of these two proteins. In summary, this study has contributed to the 
understanding of the interplay between different factors that modulate 
phosphorylation patterns and kinetics. 
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4.4 Methods 
4.4.1 Simulations and parameter estimation 
A complete description of the model and its parameters can be found in 
Chapter 3 and Appendix B. Parameter values for adaptor protein abundances, 
phosphorylation rate and dephosphorylation rate were fitted to experimental data 
using the open-source software BioNetFit (Thomas et al., 2015). This software 
uses a genetic algorithm to find the best fit. Configuration files for the fitting 
process can be found in Appendix C. A list of the values selected by the fitting 
algorithm for each parameter is presented in Table 1. 
 
Table 1. List of parameter values selected by fitting algorithm (Chapter 4) 
Parameter Parameter Value (fit) 
Grb2 concentration 3.51 x104 molecules/cell 
Shc1 concentration 4.72 x105 molecules/cell 
Phosphorylation rate 0.62 /s 
Dephosphorylation rate 1.83 /s 
 
4.4.2 Single Molecule Pull-down experiments 
For methods and reagents in SiMPull experiments please refer to Methods 
section in Chapter 2. 
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Chapter 5 : A computational model of differential signaling 
induced by EGFR ligands 
 
5.1 Introduction 
In this chapter, a computational model that could explain differential 
signaling induced by EGFR ligands is described. Wilson et. al. observed that 
stimulating cells with saturating concentrations of different ligands lead to distinct 
cellular outcomes, with the low-affinity ligands epigen and epiregulin inducing 
greater cell proliferation than the high-affinity ligand EGF (Wilson et al., 2012). 
Using protein crystallography, FRET assays and Single Particle Tracking 
(performed by me and Dr. Diane Lidke), Freed et al. showed that the epigen and 
epiregulin induced a dimer structure that lacked some key interactions which are 
present in the EGF-induced dimers, leading to less stable EGFR dimers (Freed 
et al., 2017). These differences had an effect in receptor 
phosphorylation/degradation and in both ERK and Akt activation, with 
epigen/epiregulin stimulation leading to sustained signaling, and EGF-induced 
activation having a more transient behavior, with signaling being almost 
completely null by 90 minutes. The fact that these experiments were carried out 
at saturating ligand concentrations, and that another low affinity ligand 
(amphiregulin) showed transient EGFR phosphorylation similar to the one 
induced by EGF, supported the idea that the differential response elicited by 
these ligands was due to changes in receptor stability rather than in ligand-
receptor affinity. The differences in signaling kinetics were also reflected in 
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cellular outcomes, with epigen and epiregulin leading to cell differentiation after 
long-term incubation with these ligands, and with EGF inducing cell proliferation. 
The difference in signal downregulation observed for these ligands may be 
due to a combination of multiple factors, including differences in the ability to 
recruit protein phosphatases and differences in receptor trafficking. Ligand-
dependent trafficking of EGFR has been previously reported; for example, TGF-α 
seems to preferentially induce EGFR recycling to the plasma membrane allowing 
for sustained ERK activation, whereas EGF promote receptors to be directed to 
the lysosomal pathway for degradation (Francavilla et al., 2016; Roepstorff et al., 
2009). 
The fate of EGFR after activation is also dependent on ligand 
concentration. For example, previous work suggests that low doses of EGF 
induce receptor internalization almost exclusively through clathrin-mediated 
endocytosis (CME), leading to relatively low levels of receptor degradation and 
high recycling (Sigismund et al., 2008). At high doses of EGF, a fraction of the 
receptors internalize also through CME, but another fraction internalizes through 
a type of non-clathrin mediated endocytosis that promotes receptor degradation. 
This type of endocytosis was shown to be dependent on ubiquitination of EGFR 
(Sigismund et al., 2005). One of the main proteins responsible of EGFR 
ubiquitination is the E3 ubiquitin ligase Cbl, which can be recruited directly to 
phosphorylated Y1045 in EGFR or indirectly through Grb2, with which Cbl forms 
a complex (Waterman, 2002). EGF dose-response curves of EGFR ubiquitination 
showed that receptor ubiquitination levels are low when EGF concentration is 
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below a threshold (3-10 ng/mL EGF in HeLa cells), and high after this 
concentration threshold is surpassed (Sigismund et al., 2013). On the other 
hand, receptor phosphorylation showed a more gradual increase as a function of 
EGF concentration. This behavior seems to happen at the plasma membrane, as 
it was unaffected by inhibition of receptor endocytosis by dynamin knockdown. 
Their results supported a mechanism in which Cbl-Grb2 complex is recruited in a 
cooperative fashion to receptors with dual phosphorylation at the Cbl and Grb2 
recruiting sites (pY1045-pY1068). This hypothesis was further supported by 
testing a computational model of Cbl-Grb2 cooperative recruitment and 
ubiquitination based on quantitative measurements (Capuani et al., 2015). 
Consistent with previous results, receptor ubiquitination levels directly related to 
endocytosis of the receptor through non-clathrin mediated endocytosis, leading 
to degradation.  
Using this information, it can be hypothesized that if dimer lifetimes 
induced by epiregulin or epigen are not long enough to result in significant 
simultaneous phosphorylation at Y1045 and Y1068, then only a few Cbl-Grb2 
complexes will be recruited. This, in turn, would lead to lower receptor 
ubiquitination and signal downregulation as compared to EGF stimulation. To 
help guide experimental efforts in testing this hypothesis, the computational 
model described in Chapter 3 was extended to include cooperative recruitment of 
Cbl and receptor ubiquitination, and to account for differential dimer stability 
induced by EGFR ligands. The model predicts that, in cells with low to moderate 
levels of EGFR, epiregulin will induce notably less ubiquitination than EGF and 
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explain the different signaling outputs observed. In combination with 
experiments, this model is expected to improve the quantitative understanding of 
the processes involved in differential signaling by different EGFR ligands. 
 
5.2 Results 
5.2.1 Model reproduces Y1068-Y1173 dual phosphorylation measured 
experimentally 
Before proceeding to extend the model to account for multi-
phosphorylation at the tyrosine pair relevant for Cbl recruitment and 
ubiquitination (Y1045-Y1068), the performance of this model was tested for its 
ability to reproduce phosphorylation levels of the Y1068-Y1173 pair, for which 
SiMPull data was already available. Up to this point the data that have been used 
for training and testing the model come from 2-color SiMPull experiments, in 
which the phosphorylation state of a single specific tyrosine residue is 
determined. Therefore, the model does not provide information about 
simultaneous phosphorylation at multiple sites. Chapter 2 describes an improved 
protocol to allow detection of receptor multi-phosphorylation using 3-color 
SiMPull. In those experiments, the receptors were co-labeled with spectrally 
distinct antibodies for pY1068 and pY1173, and the percent of receptors with 
simultaneous phosphorylation at these two sites was estimated. The model 
predicted that ~6.8% would be phosphorylated in both sites (Figure 5.1a). The 
percentage of dual phosphorylation estimated experimentally was similar to that 
predicted by the model (~6.8% vs ~7.2%, Figure 5.1). These results show that 
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the model is capable of making congruent predictions about dual phosphorylation 
when provided with single-site phosphorylation data of two sites. 
 
Figure 5.1. Predicted and observed dual Y1068-Y1173 phosphorylation. (a) 
Prediction of EGFR phosphorylation at sites Y1068, Y1173, and dual 
phosphorylation at these sites (pYpY). (b) Graphical representation of 3-color 
SiMPull for the analysis of individual and simultaneous phosphorylation at Y1068 
and Y1173. (c) 3-color SiMPull results for EGFR from CHO EGFR-GFP cells 
stimulated with 25 nM of EGF for 5 minutes. Error bars represent mean +/- 
S.E.M. 
 
5.2.2 Extended model for ubiquitination is able to reproduce experimental 
behavior 
The model was extended to include some of the events that impact EGFR 
ubiquitination levels at the plasma membrane: phosphorylation of tyrosine 1045, 
direct recruitment of Cbl to pY1045, indirect recruitment of Cbl through the Grb2 
and ubiquitination of EGFR by Cbl. The model also considered the cooperative 
recruitment of the Cbl-Grb2 complex to receptors phosphorylated at both Y1045 
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and Y1068 (Sigismund et al., 2013; Capuani et al., 2015). The current idea 
behind this observed cooperativity is that, when a Cbl-Grb2 complex is bound to 
one site in a dually phosphorylated receptor, the chances of (re)binding to the 
other site increases due to the increased proximity or local concentration. This, in 
turn, results in a significant increase in the time that the complex remains bound 
to these receptors.  
To capture this behavior in the model, the association constants of Cbl 
and Grb2 to the phosphorylated receptor are multiplied by a cooperativity 
constant (𝒌𝒄) in the reactions where the complex is already bound to the receptor 
and the other tyrosine residue is phosphorylated and unoccupied (Figure 5.2). In 
a similar way, if the Cbl-Grb2 complex breaks while both Cbl and Grb2 are bound 
directly to the receptor the association constant for Cbl-Grb2 is multiplied by 𝒌𝒄. 
Grb2 can also be recruited to tyrosine 1086 and contribute to the cooperative 
behavior. Comparison of a model containing one or two Grb2-binding sites 
showed that both models could fit the experimental data equally well. Thus, only 
one Grb2 binding site was considered in the model. The model also considers 
that the number of Cbl molecules available for binding to the receptor is generally 
low (~5,000-10,000 molecules/cell) compared to other adaptor proteins like Grb2 
(~1.0x105 to 1.0 x106 molecules/cell) (Shi et al., 2016; Capuani et al., 2015). 
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Figure 5.2. Graphical description of reactions included in extended model to 
consider cooperative Cbl recruitment.  𝒌𝒄 represents the cooperativity constant to 
account for increased local concentration. For simplification, the dissociation of 
the Cbl-Grb2 complex while bound to EGFR is not depicted, but in the actual 
model these reactions were included. 
 
The model was fitted to the dose-response curves of WT receptor 
ubiquitination and phosphorylation in response to EGF in HeLa cells reported by 
Sigismund et al. (2013). The dataset for ubiquitination of an EGFR mutant 
lacking the sites for Grb2 recruitment (Y->F mutations) but having Y1045 
(Y1045+) was also included for fitting the model. All parameters shared by the 
previous and extended models were kept at the same value and the parameters 
unique to the extended model were estimated (see Methods). As observed in 
Figure 5.3, the model was able to reproduce all three experimental dataset fairly 
well, with ubiquitination increase happening at lower EGF doses than 
79 
 
phosphorylation, and with ubiquitination in the Y1045+ mutant receptor being 
drastically lower than in the WT receptor (Figure 5.3a and Figure 5.3b, 
respectively). Notice that the ubiquitination levels in the model are low (~2%, 
solid red line in Figure 5.3b). The model was unable to yield a good fit for higher 
ubiquitination levels. 
 
Figure 5.3 Fitting model to experimental data. Comparison of model simulations 
(solid lines) to the experimental data (dashed lines) used for the fitting. (a) Dose-
response curve for receptor phosphorylation at tyrosine 1068 (pY) and 
ubiquitination (Ub) in cells expressing WT EGFR. (b) Ubiquitination curve for WT 
and mutant receptor devoid of the sites for Grb2 recruitment but containing the 
site for direct recruitment of Cbl (Y1045+). Data obtained from Sigismund et al. 
(2013). 
 
To validate the model, knockdown (KD) of EGFR was simulated and the 
ubiquitination dose-response curve from simulation results were compared to the 
experimental data obtained by Capuani et al. (2015) (Figure 5.4a). Consistent 
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with experimental results, model simulations showed that decreasing the number 
of EGFR molecules would result in a shift to the right of the ubiquitination curve. 
The reason for this behavior is that the number of receptors with dual 
phosphorylation at Y1045-Y1068 in the EGFR KD cells is much lower than in WT 
cells, and needs higher EGF concentrations to induce an enough receptors to be 
dually phosphorylated (and recruit Cbl efficiently) (Figure 5.4b). 
When looking at the fraction of receptors ubiquitinated instead of the 
values normalized to the maximum in Figure 5.4c, it can be observed that the 
model predicts the ubiquitination percentage to be higher in cells with fewer 
receptors (EGFR KD, 50x103 receptors) than in WT cells (250x103 receptors). 
This is consistent with the results of Capuani et al. (2016) and the idea that Cbl is 
present at a limiting concentration. To additionally validate the model, the effect 
of Cbl overexpression in receptor ubiquitination observed in this model and 
experimentally were compared (Figure 5.4d). Consistent with experimental 
results, an increase in the concentration of Cbl resulted in higher ubiquitination 
levels but did not result in a shift of the curve to the right or left. It is important to 
mention that, while this model reproduced most datasets, it was not able to 
completely match the dual phosphorylation curve at Y1045-Y1068 measured 
using co-IP WB by Sigismund et al. (2013) (Figure 5.4e). 
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Figure 5.4. Model validation: Ubiquitination in cells with EGFR knockdown or Cbl 
overexpression.  Solid lines represent results from model simulations and dashed 
lines from experimental results from the literature. (a) Knockdown (KD) of EGFR 
was simulated by a 5-fold decrease in the number of receptors per cell. (b) pYpY 
refers to pY1045-pY1068 pair. Dark line indicates the number of Cbl per cell in 
the model (5,000/cell). (c) Same as (a) but not normalized to maximum 
ubiquitination. (d) Cbl overexpression was simulated as a 2-fold increase in the 
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number of Cbl molecules per cell. (e) Comparison of dual phosphorylation in the 
model and in experimental results by Western blot. 
 
5.2.3 Model predicts impaired ubiquitination in epiregulin-stimulated MCF7 
cells 
The validated model was used to predict the effects that differences in 
ligand-dependent dimer lifetimes would have in receptor ubiquitination. Even 
though in vitro and in vivo studies suggested an important decrease in the 
stability of epiregulin-induced dimers, dimer off-rates for this condition have not 
been reported (Freed et al., 2017). Single-Particle Tracking measurements of 
EGFR dimer off-rates previously performed by Low-Nam et al. in our laboratory 
suggest that the off-rates of singly EGF-bound dimers is ~9 larger (less stable) 
than that for doubly EGF-bound dimers in HeLa cells (Low-Nam et al., 2011). 
Taking this information into consideration, as a starting point a 4 times larger 
dissociation rate for epiregulin-induced dimers than for dimers bound to two 
molecules of EGF was used in the model. On rates (dimerization rates) were 
assumed to be the same for EGF- and epiregulin-bound receptors. To simplify 
direct comparison of ubiquitination as a function of fraction of ligand-bound 
receptor, ligand concentration and affinity were kept the same for both ligands.  
Simulation results suggest that shorter-lived epiregulin dimers would not 
be able to induce as strong of ubiquitination as EGF dimers, even at saturating 
ligand concentrations in MCF7 cells, which express low levels of EGFR (Figure 
5.5a). Reduced receptor ubiquitination could result in less EGFR downregulation 
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and a more sustained signal, as observed experimentally for epiregulin and 
epigen. The predicted ligand-dependent differences in receptor phosphorylation 
can be observed in Figure 5.5b. 
 
 
Figure 5.5. Predicted ubiquitination and Y1068 phosphorylation levels in MCF7 
cells when stimulated with EGF vs epiregulin.  Levels of EGFR were set to 5,000 
receptors/cell to simulate low expression levels of EGFR observed in MCF7. 
 
 
5.2.4 Using the model to help identify the mechanisms contributing to 
epiregulin-induced sustained signaling 
Even if receptor ubiquitination is significantly lower in epiregulin-treated 
cells than in those stimulated with EGF, as predicted by the model, this would not 
rule out the possibility that other mechanisms are responsible for the prolonged 
EGFR signaling observed upon stimulation with high doses of epiregulin. 
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Therefore, the model was used to explore if there was a cellular context in which 
high doses of epiregulin were expected to achieve a similar level of receptor 
ubiquitination as doses of EGF that induce transient signaling.  
Since expression levels of EGFR were shown to alter the dose-response 
curve of receptor ubiquitination (see Figure 5.4a and (Capuani et al., 2015)), the 
number of receptors per cell in the model was modulated and the predicted 
ubiquitination curves for EGF and epiregulin for these cellular contexts were 
simulated (Figure 5.6, top). The model predicts that as EGFR expression is 
increased the ubiquitination and phosphorylation response for EGF and 
epiregulin become more similar, especially at saturating ligand concentrations. If 
these predictions are confirmed and ubiquitination is responsible for differential 
signaling, it would expected both ligands to induce similar signaling kinetics (i.e. 
transient behavior). If, instead, epiregulin-induced signaling continues to be 
sustained even when having similar levels of receptor 
phosphorylation/ubiquitination as EGF-activated receptors, it may suggest that 
sustained signaling is likely originated by another distinct property induced by 
epiregulin (e.g. ligand-receptor stability in endosomes). 
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Figure 5.6. Predicted EGF- and epiregulin-induced ubiquitination and 
phosphorylation different EGFR expression levels.  The model predicts that as 
EGFR expression levels increase, EGF vs EREG difference is less notorious. 
 
5.3 Discussion 
Previous experiments by Roepstorff et al. showed recycling of EGFR 
when stimulated with epiregulin (Roepstorff et al., 2009). Nevertheless, these 
experiments were carried out using a ligand concentration of 100 nM, which 
compared to the concentration necessary to elicit half maximum receptor 
phosphorylation in cells (20 μM) would be considered a non-saturating 
concentration (Freed et al., 2017). Therefore, it is unknown how much receptor 
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recycling and degradation is induced by high doses of ligands such as epigen 
and epiregulin. 
Our model predicted that only a low fraction of receptors (2-6%) are 
ubiquitinated at the plasma membrane level at early time points (e.g. 2 min) 
(Figure 5.3b, and top of Figure 5.6). A set of parameters values could not be 
found that resulted in higher ubiquitination levels and still fit adequately the 
experimental results. An explanation may be that in the model the stability of the 
Cbl-Grb2 complex to dually phosphorylated receptors needed to be relatively 
high (half-life > 20 seconds) in order to fit to the observed ubiquitination curves. 
The slow unbinding of this complex would limit the number of different receptors 
to which it can bind at short timescales. SiMPull assay is going to be used to test 
whether indeed only a small fraction of receptors is ubiquitinated at this time 
point. 
It is possible that only a low fraction of ubiquitinated receptors is needed to 
induce non-clathrin mediated endocytosis (NCE) of both ubiquitinated and non-
ubiquitinated receptors. It is also possible that Cbl is able to ubiquitinate not only 
the receptor to which it binds but also receptors to which it dimerizes, or nearby 
receptors in the same microdomains at the plasma membrane. It was estimated 
that ~22% of receptors are ubiquitinated in at least one site of EGFR after 5 
minutes of stimulation with a relatively high dose of EGF (20 ng/mL) (Huang et 
al., 2013). Considering that Cbl will continue to induce receptor ubiquitination 
after being endocytosed (Umebayashi et al., 2008), it is feasible that only a small 
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fraction of receptors is ubiquitinated at the membrane, as represented in our 
model.  
Our model suggested that at higher receptor concentrations than the ones 
tested experimentally (~5x103 - 50x103 receptors/cell) by Freed et al. (2017), 
there would be a dose of epiregulin that would induce similar levels of 
cooperative recruitment of Cbl and receptor ubiquitination as those induced by 
EGF at some other dose (Figure 5.6, top). It may be possible that sustained 
signaling kinetics by epiregulin will still be observed in these conditions. If that is 
the case, one possible explanation would be that the nature of the ubiquitination 
induced by epiregulin and EGF may be different (e.g. different levels of mono- vs 
poly-ubiquitination), even if the total ubiquitination measured is similar. Another 
possibility may lie in differences in receptor trafficking induced by factors other 
than ubiquitination, such as stability of the ligand-receptor complex inside 
endosomes. This could happen either by changes in endosomal pH or by ligand 
unbinding at endosomes, as suggested for the high-affinity ligand for EGFR TGF-
α and the low-affinity ligand for EGFR amphiregulin, respectively (Ebner and 
Derynck, 1991; Roepstorff et al., 2009). 
Quantitative measurements will be performed to test the predictions made 
by the computational model. This will contribute to gaining mechanistic insights 
about the processes involved in differential signaling induced by EGFR ligands. 
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5.4 Methods 
5.4.1 Simulations and parameter estimation 
Parameter values used in the fitted model of the previous chapter were 
used for the extended model presented here. A complete list of parameters and 
reaction rules used for this model can be found in Appendix B. A list of the 
parameters fitted using BioNetFit for this model, and the values selected by the 
fitting algorithm, can be found in Table 2. Configuration files for the fitting process 
can be found in Appendix C. 
 
Table 2. List of parameter values selected by fitting algorithm (Chapter 5) 
Parameter Parameter Value (fit) 
Kd Cbl-pY1045* 2.51 x10-7 M 
Kd Cbl-Grb2 7.24 x10-7 M 
Cooperativity constant 2.59 x108 
Ubiquitination rate 5.26 x10-2 /s 
Deubiquitination rate 1.71 x10-2 /s 
* Kd Cbl-pY1045 means dissociation constant (in molar units) between Cbl and 
pY1045 in EGFR. 
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Chapter 6 : Implications and Future Studies 
 
6.1 Implications 
6.1.1 Significance of improvements made on SiMPull technique  
The improvements made on the SiMPull technique allows for the 
quantification of the heterogeneity in the activation states of single molecules. 
The majority of the proteins involved in signaling have multiple sites of 
phosphorylation and other post-translational modifications. Therefore, these 
improvements should prove useful in the study of other signaling players. 
Additionally, some of the improvements made for quantification of receptor 
phosphorylation, like reduction of background fluorescence, can be useful for 
when doing traditional SiMPull where the intention is to quantify the 
heterogeneity in composition of protein complexes.  
 
6.1.2 Significance of understanding role of adaptor protein abundances in 
biased phosphorylation  
By studying the quantitative relation between adaptor proteins and 
phosphorylation, the quantitative understanding of the different factors affecting 
phosphorylation levels has been improved. This information can be included in 
future computational models to have a more realistic representation of the 
processes modulating phosphorylation. The understanding of the phospho-site 
protection mechanism described could also help interpreting results in which 
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variations in protein abundances are involved, as the possibility of protection 
from phosphatases is not commonly considered. For example, if the 
phosphorylation levels of two sites are correlated, one hypothesis would be that 
phosphorylation of one site promotes the phosphorylation of the second, or vice 
versa, as hypothesized by Coba et al. when observing correlation between 
phosphorylated sites of a neuronal signaling pathway (Coba et al., 2009). But it 
can also be that the correlation is due to an adaptor protein protecting two nearby 
sites from dephosphorylation. Additionally, understanding the relation of adaptor 
protein abundances and phosphorylation could help understand what happens in 
cancer cells that overexpress certain adaptor proteins. 
 
6.1.3 Significance of rule-based model for EGFR activation and 
ubiquitination by different ligands  
By testing the predictions generated by the model described, it is expected 
that a better mechanistic understanding of differential signaling induced by EGFR 
ligands will be gained. Understanding how dimer lifetimes translates into different 
signaling outcomes can be helpful in understanding differences in signaling 
observed with other ligands, or in other membrane receptors whose binding 
lifetimes are different to those of EGFR. The rule-based model created in this 
work can be adapted to represent activation of these receptors. Additionally, this 
knowledge can be useful in designing intelligent modulators of signaling protein 
interactions to promote signal downregulation in diseases such as cancer. 
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6.2 Future Studies 
6.2.1 Effects of adaptor protein abundances in downstream signaling and 
cellular outcomes 
To gain a deeper quantitative understanding of the relationship between 
protein abundances and phosphorylation levels, our team is generating a series 
of HeLa S3 clones in which one or two copies of the genes encoding for Grb2 
and Shc1 have been knocked out using CRISPR engineering. 
Cancer cells commonly have altered expression of signaling proteins. 
Therefore it would be interesting to know what the effects of these alterations in 
signaling are. For example, the ERK pathway has been shown to be activated at 
very low doses of EGF, therefore it would be interesting to know if Grb2 
overexpression leads to ERK activation happening at even lower doses, or if it 
makes the activation stronger. When looking at the effect of protein 
overexpression, it is difficult to distinguish how much of the observed effect is 
due to protein availability itself and how much due to site protection. To evaluate 
these contributions, a model where sites are not protected by adaptor proteins 
could be created. 
 
6.2.2 Experimental testing of model predictions for differential 
ubiquitination induced by EGFR ligands 
Measurements of ubiquitination levels in MCF7 (~5,000 receptors/cell) or 
T47D (~50,000 receptors/cell) cells in response to saturating concentrations of 
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EGF and EREG will be performed, in order to see if, as predicted by our model, 
differential ubiquitination is observed. These measurements could be performed 
first by Western blot and if a difference is observed, then SiMPull experiments for 
ubiquitination can be performed. This would provide the percent of receptors 
ubiquitinated and would be very useful to compare with the current model, which 
predicts low ubiquitination percentages (2-6%).  Another experiment that would 
provide useful information to refine the model would be to measure 
phosphorylation at Y1045 with SiMPull. The anti-pY1045 antibody is available in 
the lab and it will be labeled for use in SiMPull experiments in the near future. 
Also, it is likely dual phosphorylation at Y1045-Y1068 with SiMPull will be 
performed. Considering the close proximity of these sites, there may be problems 
with steric hindrance between these antibodies, in which case, Fab fragments 
could be generated to decrease chances of steric hindrance. 
Additionally, it is going to be tested if phosphorylation and ubiquitination 
induced by the two ligands become more similar in cells expressing higher levels 
of receptors, as predicted by the model. If that is the case, then it would be 
interesting to check if the signaling kinetics is also similar (i.e. transient), 
supporting the role for ubiquitination in biased signaling. If that is not the case, 
other mechanisms may be involved, for example differences in ligand-receptor 
stability in endosomes. EGF has been shown to still induce strong 
phosphorylation in early endosomes (Francavilla et al., 2016), but if EREG 
stability decreases in endosomes it could be expected to have lower 
phosphorylation in early endosomes, and likely increased receptor recycling. This 
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can be tested by using confocal microscopy by labeling for markers of early 
endosomes (e.g. Rab5) and EGFR phosphorylation, and also labeling for 
recycling markers (e.g. Rab11). 
 
6.2.3 Study phosphorylation and downstream signaling of EGFR mutant 
L858R 
The L858R EGFR mutant, involved in Non-Small Cell Lung Cancer, has 
been shown to have increased kinase activity and increased dimer stability 
(Zhang et al., 2006; Valley et al., 2015). It would be interesting to explore what 
are the effects of these altered kinetic parameters in biased phosphorylation and 
in receptor multi-phosphorylation. Preliminary results using 3-color SiMPull show 
that even though the levels of phosphorylation increase, the biased 
phosphorylation still remains (Figure 6.1).  
 
Figure 6.1. Single- and multi-phosphorylation in WT vs L858R mutant receptor.  
Receptors expressed in CHO cells. Receptors were labeled using an anti-pY 
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(pan-pY) antibody. An anti-EGFR antibody will be used in future experiments to 
label the receptors. Error bars represent mean +/- S.E.M. 
It would also be relevant to understand how dual phosphorylation at 
Y1045-Y1068 and receptor ubiquitination is affected in the mutant receptor. 
Shtiegman et al. showed that Cbl recruitment to L858R EGFR and receptor 
ubiquitination were decreased compared to WT, even when Y1045 and Y1068 
were more phosphorylated  (Shtiegman et al., 2007). Their results suggest that 
by favored heterodimerization with HER2 this mutant evades Cbl recruitment and 
ubiquitination. It would be interesting to know if receptor ubiquitination is 
increased in this mutant in the absence of HER2, and explore how these 
changes affect downstream signaling and cellular outcomes. 
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APPENDIX A: MATLAB scripts for analysis of SiMPull data 
This script was used to localize and process SiMPull data. 
 
% Script to overlay fitting in 2 channels 
close all; 
clear all 
clear dat 
  
  
% Instructions: copy this script inside a 'scripts' folder located in 
the 
% same location as the files to be analyzed. Copy correct channel 
% registration file name. Set threshold for the 3 channels (488 top-
right, 
% 561 top-left, and 642 bottom-left; use 
% thresholdTest.m to assess your decision). Use joinSequentialCh to 
join 
% the 3 channels in single images (it creates "joined_" files). Use 
formatFilenames.m to create 
% list of files ("joined_" files) and 4D-dipimage to assess frames that 
should be excluded for 
% analysis (bad frames). 
  
% This version (v2_03) allows definin the min P value to filter fits 
for 
% each individual channel. Therefore you can filter out only irregular 
GFP 
% molecules that are probably more than one receptors in close 
proximity 
  
% This version (v2_02) saves the coordinates of the triple overlay GFP 
% molecules in the variable 'coordTripleOv'. 
  
% This version (v2_01) got significantly modified in order to be able 
to 
% use the new Registration Class that Mark wrote. In order to analyze 
the 
% fiducial (now acquired using nanogrid) you should use Matlab 2015a or 
% later versions. 
  
% This version (v1_04) don't sum the frame selected and the previous 
one, 
% only the frame specified, given that now we are using an automated 
% process for the data acquisition and the shutters from the lasers and 
the 
% camera are coordinated. 
  
% This version (v1_05) take first image in from right channel and 
second 
% from left channel because for some reason the green laser (right ch) 
started 
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% turning on from the first frame acquired (frame 0), when normally is 
from 
% the second frame (frame 1) 
  
% This version (v1_06) is the v1_05 adapted to get the fields of view 
from 
% the new QuadView setting. These fields of view are of 256x256 (double 
% than before) and we image only 9 fields of view instead of 36. 
  
% This version (v1_06_3color) is the v1_06 adapted to analyze and 
overlay 
% the 3 channels (488 top-right, 561 top-left, and 642 bottom-left) 
  
% This version (v1_07_3color) fixed some errors 
% v1_06_3color had in quantifying % of 561 spots with overlapping 642, 
and 
% included quantification for overlapping of spots of the three 
channels 
% (triple overlap) 
  
% This version (v1_08_3color) is the v1_07_3color adapted to analyze 
and overlay 
% the 3 channels (488 top-right, 561 top-left, and 642 bottom-left) 
% acquired with the new laser and instrumentation class. Here the 3rd 
% dimension indicates the number of frame or field of view, and the 4th 
% indicates the 3 different channels/lasers (642 first, 561 second and 
488 
% last, acquired sequentially to prevent bleed through and bleaching). 
  
% Version v1_09_3color is v1_08_3color but with higher P value 
threshold to 
% prevent considering very bright crap that fluoresces in 2 or 3 
channels 
% and that would be otherwise considered phospohrylated receptors. (P 
value 
% changed to   instead of 0.0) 
  
  
intperframe_488= 700; % Intensity to use for thresholding per frame in 
the respective channels. 
intperframe_561= 600; 
intperframe_642= 200; 
minPValue_488= 1e-99;%1e-99;2e-1 % Minimum P value for filtering 
fits(the bigger the more fits will reject) 
minPValue_561= 0;%1e-99; % Minimum P value for filtering fits(the 
bigger the more fits will reject) 
minPValue_642= 0;%1e-99; % Minimum P value for filtering fits(the 
bigger the more fits will reject) 
  
% define files 
cd .. % change current directory to one level up 
filedir= pwd; % use current directory as filedir  
% filedir='E:\Emanuel\DATA\SiMPull\150803 CHO EGFR-GFP A647-NHS-ester 
surface'; 
paramsfile=[filedir '\scripts\SPTparams.mat']; 
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% Create folder to save files for tracking 
savedir=fullfile(filedir,'totrack'); 
if ~exist(savedir, 'dir') 
  mkdir(savedir); 
end 
  
% Create folder to save files to save figures 
savedirFigs=fullfile(filedir,'Figures'); 
if ~exist(savedirFigs, 'dir') 
  mkdir(savedirFigs); 
end 
  
% Defined location and name of Registration Analysis files 
regAnal561file=[filedir '\fiducial\RegAnal_A488_561.mat']; 
regAnal642file=[filedir '\fiducial\RegAnal_A488_642.mat']; 
  
  
  
% Set file info 
 
  
% Small sample of files for dissertation 
 
dat(1).filename='joined_CHO-ErbB1-GFP_5min-10nM-EGF_anti-EGFR-
AF555_pY1068-CF640R-2018-2-1-17-45-13'; 
badFrames{1}= []; 
  
dat(2).filename='joined_CHO-ErbB1-GFP_5min-10nM-EGF_anti-EGFR-
AF555_pY1068-CF640R-2018-2-1-17-47-29'; 
badFrames{2}= [1]; 
  
dat(3).filename='joined_CHO-ErbB1-GFP_5min-10nM-EGF_anti-EGFR-
AF555_pY1068-CF640R-2018-2-1-17-47-51'; 
badFrames{3}= []; 
  
dat(4).filename='joined_CHO-ErbB1-GFP_5min-10nM-EGF_anti-EGFR-
AF555_pY1068-CF640R-2018-2-1-17-48-11'; 
badFrames{4}= [1:3]; 
  
dat(5).filename='joined_CHO-ErbB1-GFP_5min-10nM-EGF_anti-EGFR-
AF555_pY1068-CF640R-2018-2-1-17-48-50'; 
badFrames{5}= [1]; 
  
dat(6).filename='joined_CHO-ErbB1-GFP_5min-10nM-EGF_anti-EGFR-
AF555_pY1068-CF640R-2018-2-1-17-49-48'; 
badFrames{6}= [1 2]; 
  
 
 
  
  
  
for iiDat=1:length(dat) 
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    goodFrames{iiDat}= 1:3; % Initialize good frames (it doesn't take 
consider first and last frame (0 and 4) because they are used for 
focusing) 
    goodFrames{iiDat}([badFrames{iiDat}])= []; % Remove bad frames 
    for iiFrame=1:length(goodFrames{iiDat}) 
        dat(iiDat).frms{iiFrame}=goodFrames{iiDat}(iiFrame); % create 
structure with frames to be analyzed 
    end 
end 
  
  
  
  
  
% Load Registration Analysis files and get transformation function 
% Transform 561 based on 488 
load(regAnal561file) 
SXS = RA.SensorXSplit;      % channel 2 x-coordinates should be > SXS 
% Construct the mapping from the right channel to the left. 
% Note that mapping occurs in absolute coordinates. 
% Optimal map: 
M561 = RA.getOptimalMapPixels(); 
% Maps by algorithm: 
%    (1) Null 
%    (2) GlobalAffine 
%    (3) LocalAffine 
%    (4) SmoothAffine 
%    (5) LWM 
%    (6) Polynomial 
%    (7) NRS 
%M = RA.maps(5).mapFunctionPixels; 
  
% Transform 642 based on 488load(regAnal561file) 
load(regAnal642file) 
SXS = RA.SensorXSplit;      % channel 2 x-coordinates should be > SXS 
M642 = RA.getOptimalMapPixels(); 
  
  
  
totFrms= 0; % Initialize total number of frames to be analyzed 
% Calculate total number of frames to be analyzed 
for ii=1:size(dat,2) 
    totFrms= totFrms+size(dat(ii).frms(:),1); 
end 
  
% Before looping through initiate define column identifiers and 
'valuecell' 
% to store the numbers of found fits 
  
% define column identifiers 
colIdent= {'FileName', '488-fits','561-fits','642-fits',... 
'488-561-overlaps','488-642-overlaps','561-642-overlaps','Triple-
overlap',... 
'% 488 w/561','Average %','% 488 w/642','Average %','% 488 w/561-
642','Average %',... 
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'% 488-561 w/642','Average %','% 488-642 w/561','Average %'}; 
  
  
valuecell= cell(totFrms+1,numel(colIdent)); 
valuecell(1,:)= colIdent; 
absFrameNum= 0; % Absolute frame number (to correctly place info in 
cell array 'valuecell') 
blnk=dip_image(zeros(256,256)); % Blank image used in the process of 
building gaussian blob images 
  
% loop through each movie defined above 
for ii=1:size(dat,2) 
     load(fullfile(filedir,dat(ii).filename));  
     % because sequence var gets re-written need to rename, Now 
     % I'm using dataset instead of sequence so this renaming may 
     % be unnecesary in the future 
    for jj=1:length(dat(ii).frms) 
        clear sptObj642 sptObj488 test currfrms image_out c svfilename 
TrackXY642 TrackXY488 tots488 tots642 
         
        absFrameNum= absFrameNum+1; % Absolute frame number (to 
correctly place info in cell array 'valuecell') 
        
        % process image, crop and save 
        currfrms=dat(ii).frms{jj}; % variable for the current frames to 
analyze 
        fullsequence=squeeze(datasetJoined(:,:,:));  
        test_488=sum(fullsequence(:,:,currfrms),[],3); % do a sum 
projection of all frames 
        test_488=squeeze(test_488); 
         
        fullsequence=squeeze(datasetJoined(:,:,:));  
        test_561=sum(fullsequence(:,:,currfrms),[],3); % do a sum 
projection of all frames 
        test_561=squeeze(test_561); 
         
        fullsequence=squeeze(datasetJoined(:,:,:)); 
        test_642=sum(fullsequence(:,:,currfrms),[],3); % do a sum 
projection of all frames 
        test_642=squeeze(test_642); 
         
        svfilename=[dat(ii).filename '_' mat2str(currfrms(1)-1) '-' 
mat2str(currfrms(size(currfrms,2)))]; % create filestring with filename 
and frame range 
         
        dipsetpref('DefaultFigureWidth', 512,'DefaultFigureHeight', 
512); % set default width of window to 512 to display next image 
properly 
        h_raw=dipshow(test_642); % use to show the image 
%         saveas(h_raw,fullfile(savedirFigs,[svfilename 
'_raw.png']),'png') 
        saveas(h_raw,fullfile(savedirFigs,[svfilename 
'_raw.fig']),'fig') 
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        % create sequence of 5 frames- just repeated image so that SPT 
code can be 
        % used for fitting 
        sequence=repmat(test_488(256:end,0:255),[1 1 5]); 
        save(fullfile(savedir,[svfilename '_488.mat']),'sequence'); % 
save 488 of image 
         
        sequence=repmat(test_561(0:255,0:255),[1 1 5]); 
        save(fullfile(savedir,[svfilename '_561.mat']),'sequence'); % 
save 561 of image 
         
        sequence=repmat(test_642(0:255,256:511),[1 1 5]); 
        save(fullfile(savedir,[svfilename '_642.mat']),'sequence'); % 
save 642 of image 
         
                  
          
          
          
        %use spt to find positions of 488 channel 
        params=load(paramsfile); 
        sptObj488=SPT; 
        sptObj488.DataFile=fullfile(savedir,[svfilename '_488.mat']) 
        sptObj488.setParams(params); 
        
sptObj488.ParamsFindBoxCenters.MinPhotons=size(currfrms,2)*intperframe_
488; 
%         sptObj488.ParamsFindBoxCenters.maxPixelRegionSize=1; % change 
        sptObj488.findBoxCenters 
        % To prevent error if there are no spots in the image 
        if size(sptObj488.BoxCenters,1) == 0 
            TrackXY488 = []; 
        else 
             
        % 
%         sptObj488.ParamsFilterFits.MinPhotons=.0001; 
        sptObj488.ParamsFilterFits.MinPValue= minPValue_488; 
        sptObj488.filterFits; 
         
         %to view overlay of fits and raw data (note that fits are 
shifted already) 
        %         sptObj488.plotFitResults %plot results to compare 
        %          sptObj488.SaveBaseName=fullfile(savedir,[svfilename 
        %          '_488.mat']); --don't actually need this 
        sptObj488.saveFile(0); 
         
        % create gaussian blob series of 488 data (no shifting) 
        TrackXY488=[sptObj488.FitResults(1).xCoord(:,1) 
sptObj488.FitResults(1).yCoord(:,1)]; %must be Nx2 matrix 
        end 
        clear blnktot 
        blnk=dip_image(zeros(256,256)); 
        if size(TrackXY488,1) == 1  % if statement added to avoid 
creating a 2D instead of a 3D dip image when there are no spots 
            blnktot= dip_image(zeros(256,256,2)); 
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            blnktot= blnktot(:,:,1); 
        else 
            blnktot=dip_image(zeros(256,256,size(TrackXY488,1))); 
        end 
        for kk=1:size(TrackXY488,1) 
            blnktot(:,:,kk-
1)=gaussianblob(blnk,TrackXY488(kk,:),1,5000,'spatial',3); 
        end 
        tots488=sum(blnktot,[],3); 
         
         
         
         
        %use SPT to find positions of 561 channel 
        params=load(paramsfile); 
        sptObj561=SPT; 
        sptObj561.DataFile=fullfile(savedir,[svfilename '_561.mat']) 
        sptObj561.setParams(params); 
        
sptObj561.ParamsFindBoxCenters.MinPhotons=size(currfrms,2)*intperframe_
561; %have intensity value proportional to # of frames summed 
%         sptObj561.ParamsFindBoxCenters.maxPixelRegionSize=1; % change 
        sptObj561.findBoxCenters 
        % To prevent error if there are no spots in the image (below is 
        % more code to prevent same error) 
        if size(sptObj561.BoxCenters,1) == 0 
            ShiftedTrackXY561 = []; 
            TrackXY561 = []; 
             
        else 
%         sptObj561.ParamsFilterFits.MinPhotons=.0001; 
        sptObj561.ParamsFilterFits.MinPValue= minPValue_561; 
        sptObj561.filterFits; 
        %         sptObj561.plotFitResults %plot results to compare 
        %         sptObj561.SaveBaseName=fullfile(savedir,[svfilename 
'_561.mat']); --don't actually need this 
        sptObj561.saveFile(0); % save .spt files 
         
        % Shift tracks from 561 channel 
        TrackXY561=[sptObj561.FitResults(1).xCoord(:,1) 
sptObj561.FitResults(1).yCoord(:,1)]; %must be Nx2 matrix 
        % Adding SXS pixels shifts channel 2 x-coordinates from 
relative coordinates 
        % with channel 2 in isolation back to the absolute coordinates 
used to 
        % construct the map with the channels side-by-side.  The 
mapping then 
        % transforms channel 2 into the coordinate space of channel 1. 
        [ ShiftedTrackXY561 ] = M561([TrackXY561(:, 1) + SXS, 
TrackXY561(:, 2)]); 
        save(fullfile(savedir,[svfilename '_561shiftedvals.mat']), 
'ShiftedTrackXY561'); %save shifted values 
        end 
         
        % create gaussian blob series of shifted data 
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        % Code modified to prevent error when 1 spot 
        clear blnktot 
        blnk=dip_image(zeros(256,256)); 
        if size(ShiftedTrackXY561,1) == 1  % if statement added to 
avoid creating a 2D instead of a 3D dip image when there are no spots 
            blnktot= dip_image(zeros(256,256,2)); 
            blnktot= blnktot(:,:,1); 
        else 
            
blnktot=dip_image(zeros(256,256,size(ShiftedTrackXY561,1))); 
        end 
        
        for kk=1:size(ShiftedTrackXY561,1) 
            blnktot(:,:,kk-
1)=gaussianblob(blnk,ShiftedTrackXY561(kk,:),1,5000,'spatial',3); 
        end 
        tots561=sum(blnktot,[],3); 
%          joinchannels('rgb',c(0:255,:),squeeze(tots561)*10) %-- 
uncomment 
         
         
         
         
        %use SPT to find positions of 642 channel 
        params=load(paramsfile); 
        sptObj642=SPT; 
        sptObj642.DataFile=fullfile(savedir,[svfilename '_642.mat']) 
        sptObj642.setParams(params); 
        
sptObj642.ParamsFindBoxCenters.MinPhotons=size(currfrms,2)*intperframe_
642; %have intensity value proportional to # of frames summed 
%         sptObj642.ParamsFindBoxCenters.maxPixelRegionSize=1; % change 
        sptObj642.findBoxCenters 
        % To prevent error if there are no spots in the image (below is 
        % more code to prevent same error) 
        if size(sptObj642.BoxCenters,1) == 0 
            ShiftedTrackXY642 = []; 
            TrackXY642 = []; 
             
        else 
%         sptObj642.ParamsFilterFits.MinPhotons=.0001; 
        sptObj642.ParamsFilterFits.MinPValue= minPValue_642; 
        sptObj642.filterFits; 
        %         sptObj642.plotFitResults %plot results to compare 
        %         sptObj642.SaveBaseName=fullfile(savedir,[svfilename 
'_642.mat']); --don't actually need this 
        sptObj642.saveFile(0); % save .spt files 
         
        % Shift tracks from 642 channel 
        TrackXY642=[sptObj642.FitResults(1).xCoord(:,1) 
sptObj642.FitResults(1).yCoord(:,1)]; %must be Nx2 matrix 
        % Adding SXS pixels shifts channel 2 x-coordinates from 
relative coordinates 
        % with channel 2 in isolation back to the absolute coordinates 
used to 
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        % construct the map with the channels side-by-side.  The 
mapping then 
        % transforms channel 2 into the coordinate space of channel 1. 
        [ ShiftedTrackXY642 ] = M642([TrackXY642(:, 1) + SXS, 
TrackXY642(:, 2)]);         
        save(fullfile(savedir,[svfilename '_642shiftedvals.mat']), 
'ShiftedTrackXY642'); %save shifted values 
        end 
         
        % create gaussian blob series of shifted data 
        % Code modified to prevent error when 1 spot 
        clear blnktot 
        blnk=dip_image(zeros(256,256)); 
        if size(ShiftedTrackXY642,1) == 1  % if statement added to 
avoid creating a 2D instead of a 3D dip image when there are no spots 
            blnktot= dip_image(zeros(256,256,2)); 
            blnktot= blnktot(:,:,1); 
        else 
            
blnktot=dip_image(zeros(256,256,size(ShiftedTrackXY642,1))); 
        end 
        
        for kk=1:size(ShiftedTrackXY642,1) 
            blnktot(:,:,kk-
1)=gaussianblob(blnk,ShiftedTrackXY642(kk,:),1,5000,'spatial',3); 
        end 
        tots642=sum(blnktot,[],3); 
%          joinchannels('rgb',c(0:255,:),squeeze(tots642)*10) %-- 
uncomment 
  
  
         
         
        % To prevent error if there are no spots in any of the channels 
        % when trying to overlay shifted blobs  
         
        if size(TrackXY488,1)==0 
            tots488= dip_image(zeros(256,256,2)); 
            tots488= tots488(:,:,1); 
        end 
         
         
        if size(ShiftedTrackXY561,1)==0 
            tots561= dip_image(zeros(256,256,2)); 
            tots561= tots561(:,:,1); 
        end 
         
         
        if size(ShiftedTrackXY642,1)==0 
            tots642= dip_image(zeros(256,256,2));  % if statement added 
to avoid creating a 2D instead of a 3D dip image when there are no 
spots 
            tots642= tots642(:,:,1); 
        end      
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        % overlay shifted blobs on raw data 
        ovlayimage=joinchannels('rgb',tots642,tots488,tots561); 
        h_raw=dipshow(ovlayimage); % use to show the image 
         
        % save shifted images 
        saveas(h_raw,fullfile(savedirFigs,[svfilename 
'_overlayedchannels.fig']),'fig') 
        saveas(h_raw,fullfile(savedirFigs,[svfilename 
'_overlayedchannels.png']),'png') 
%         close(h)% close image after saving 
         
  
        % Calculate number of spots in 561 channel overlapping with 
spots in 488 channel  
        clear blnktot 
         
        if size(ShiftedTrackXY561,1) <= 1  % "if" statement added to 
avoid creating a 2D instead of a 3D dip image when there are only 1 or 
no spots 
            blnktot= dip_image(zeros(256,256,2)); 
            blnktot= blnktot(:,:,1); 
        else 
            
blnktot=dip_image(zeros(256,256,size(ShiftedTrackXY561,1))); 
        end 
        numoverlap561w488 = 0; % number of overlapping blobs 
        pixallow = 1.0; % number of pixels allowed to be shifted 
between overlapping blobs to consider them as being the same molecule 
  
        for mm=1:size(ShiftedTrackXY561,1) 
            for nn=1:size(TrackXY488,1) 
                if abs(ShiftedTrackXY561(mm,:)-TrackXY488(nn,:)) < 
pixallow 
                    numoverlap561w488 = numoverlap561w488+1;  
                    blnktot(:,:,mm-
1)=gaussianblob(blnk,ShiftedTrackXY561(mm,:),1,5000,'spatial',3); 
                end 
            end 
        end 
        tots561ov488=sum(blnktot,[],3); % image with total overlapping 
blobs in left channel 
  
         
         
        % Calculate number of spots in 642 channel overlapping with 
spots in 488 channel  
        clear blnktot 
         
        if size(ShiftedTrackXY642,1) <= 1  % "if" statement added to 
avoid creating a 2D instead of a 3D dip image when there are only 1 or 
no spots 
            blnktot= dip_image(zeros(256,256,2)); 
            blnktot= blnktot(:,:,1); 
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        else 
            
blnktot=dip_image(zeros(256,256,size(ShiftedTrackXY642,1))); 
        end 
        numoverlap642w488 = 0; % number of overlapping blobs 
        pixallow = 1.0; % number of pixels allowed to be shifted 
between overlapping blobs to consider them as being the same molecule 
  
        for mm=1:size(ShiftedTrackXY642,1) 
            for nn=1:size(TrackXY488,1) 
                if abs(ShiftedTrackXY642(mm,:)-TrackXY488(nn,:)) < 
pixallow 
                    numoverlap642w488 = numoverlap642w488+1;  
                    blnktot(:,:,mm-
1)=gaussianblob(blnk,ShiftedTrackXY642(mm,:),1,5000,'spatial',3); 
                end 
            end 
        end 
        tots642ov488=sum(blnktot,[],3); % image with total overlapping 
blobs in left channel 
         
         
         
        % Calculate number of spots in 642 channel overlapping with 
spots in 561 channel  
        clear blnktot 
         
        if size(ShiftedTrackXY642,1) <= 1  % "if" statement added to 
avoid creating a 2D instead of a 3D dip image when there are only 1 or 
no spots 
            blnktot= dip_image(zeros(256,256,2)); 
            blnktot= blnktot(:,:,1); 
        else 
            
blnktot=dip_image(zeros(256,256,size(ShiftedTrackXY642,1))); 
        end 
        numoverlap642w561 = 0; % number of overlapping blobs 
        pixallow = 1.0; % number of pixels allowed to be shifted 
between overlapping blobs to consider them as being the same molecule 
  
        for mm=1:size(ShiftedTrackXY642,1) 
            for nn=1:size(ShiftedTrackXY561,1) 
                if abs(ShiftedTrackXY642(mm,:)-ShiftedTrackXY561(nn,:)) 
< pixallow 
                    numoverlap642w561 = numoverlap642w561+1;  
                    blnktot(:,:,mm-
1)=gaussianblob(blnk,ShiftedTrackXY642(mm,:),1,5000,'spatial',3); 
                end 
            end 
        end 
        tots642ov561=sum(blnktot,[],3); % image with total overlapping 
blobs in left channel 
         
         
         
106 
 
        % Calculate number of spots overlapping in the three channels 
(488, 561 and 642) 
        clear blnktot 
         
        if size(ShiftedTrackXY642,1) <= 1  % "if" statement added to 
avoid creating a 2D instead of a 3D dip image when there are only 1 or 
no spots 
            blnktot= dip_image(zeros(256,256,2)); 
            blnktot= blnktot(:,:,1); 
        else 
            
blnktot=dip_image(zeros(256,256,size(ShiftedTrackXY642,1))); 
        end 
        numTripleOverlap = 0; % number of overlapping blobs 
        coordTripleOv = zeros(size(TrackXY488,1),2); % empty array to 
place coordinates of 488 with triple overlap 
        pixallow = 1.0; % number of pixels allowed to be shifted 
between overlapping blobs to consider them as being the same molecule 
  
        for mm=1:size(ShiftedTrackXY642,1) 
            for nn=1:size(ShiftedTrackXY561,1) 
                if abs(ShiftedTrackXY642(mm,:)-ShiftedTrackXY561(nn,:)) 
< pixallow 
                    % If 642 spot overlaps with 561, then loop through 
the 
                    % 488 spots to check if it also overlaps with 488 
spot 
                    for nnTriple=1:size(TrackXY488,1) 
                        if abs(ShiftedTrackXY642(mm,:)-
TrackXY488(nnTriple,:)) < pixallow 
                            numTripleOverlap = numTripleOverlap+1; 
                            coordTripleOv(numTripleOverlap,:)= 
TrackXY488(nnTriple,:); % store number of tracks in 488 channel that 
have triple overlap 
                            blnktot(:,:,mm-
1)=gaussianblob(blnk,ShiftedTrackXY642(mm,:),1,5000,'spatial',3); 
                        end 
                    end 
                                         
                end 
            end 
        end 
        totsTripleOverlap=sum(blnktot,[],3); % image with total 
overlapping blobs in left channel 
         
        % Remove rows with all zeros and save coordinates 
        coordTripleOv(all(coordTripleOv==0,2),:)=[]; 
        save(fullfile(savedir,[svfilename 
'_488_tripleOverlapCoord.mat']), 'coordTripleOv'); 
  
         
         
        % Display image with only of those spots overlapping with the 
ones 
        % in 488 channel 
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        if isempty(tots642ov488)==0 || isempty(tots561ov488)==0 
        
ovlayOnly=joinchannels('rgb',tots642ov488,tots488,tots561ov488); % 
shows all green blobs and only those red (642) and blue (561) blobs 
that overlay 
        h_ovlayOnly=dipshow(ovlayOnly); % use to show the image 
        saveas(h_ovlayOnly,fullfile(savedirFigs,[svfilename 
'_overlayW488only.png']),'png') 
        else 
        end 
         
%         % Display image with only of those 642 spots overlapping with 
the ones 
%         % in 561 channel 
%         if isempty(tots642ov561)==0 
%         ovlayOnly=joinchannels('rgb',tots642ov561,tots488,tots561); % 
shows all green blobs and only those red blobs that overlay 
%         h_ovlayOnly=dipshow(ovlayOnly); % use to show the image 
%         saveas(h_ovlayOnly,fullfile(savedirFigs,[svfilename 
'_overlaySpotsOnly.png']),'png') 
%         else 
%         end 
         
         
        % For reference below are the current column identifiers for 
the 
        % cell array or spread sheet 
%         colIdent= {'FileName', '488-fits','561-fits','642-fits',... 
%         '488-561-overlaps','488-642-overlaps','561-642-
overlaps','Triple-overlap',... 
%         '% 488 w/561','Average %','% 488 w/642','Average %','% 488 
w/561-642','Average %',... 
%         '% 488-561 w/642','Average %','% 488-642 w/561','Average %'}; 
  
        % Concatenate results to cell array (see column identifiers 
above) 
        % Add 1 (+1) to absFrameNum to count for column identifiers 
        
valuecell(absFrameNum+1,:)={svfilename,size(TrackXY488,1),size(TrackXY5
61,1),size(TrackXY642,1)... 
            
,numoverlap561w488,numoverlap642w488,numoverlap642w561,numTripleOverlap
,... 
            
numoverlap561w488/size(TrackXY488,1)*100,'',numoverlap642w488/size(Trac
kXY488,1)*100,'',numTripleOverlap/size(TrackXY488,1)*100,'',... 
            
numTripleOverlap/numoverlap561w488*100,'',numTripleOverlap/numoverlap64
2w488*100,''};  
         
        % Create overlayed localizations and raw data 
        locMask= newim(512,512); % Create figure to save mask with 
localizations 
        locMask(256:end,0:255)= squeeze(tots488>600); % Add mask to 
corresponding areas/channel 
        locMask(0:255,0:255)= squeeze(tots561>600); 
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        locMask(0:255,256:511)= squeeze(tots642>600);           
         
        h_rawOverlay=dipshow(overlay(test_642,locMask,[15000,0,0])); % 
use to show the image 
        saveas(h_rawOverlay,fullfile(savedirFigs,[svfilename 
'_rawOverlayLoc.fig']),'fig') 
         
  
    end 
    close all 
end 
  
  
  
%after loop write to excel and matlab files 
xlswrite([filedir '\results.xls'],valuecell) % data saved in excel file 
save([filedir '\results.mat'],'valuecell','coordTripleOv') % data saved 
in matlab file 
  
cd scripts % change current directory back to scripts folder 
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APPENDIX B: BNGL files of rule-based models 
 
BNGL file for model in Chapter 4 
begin model 
 
 
# References 
# 1. Hause et al., 2012. Plos ONE. 
# 2. Engelmann BW et al., 2014. Mol Cell Proteomics. 
# 3. Kulak NA et al. (2014) Nat Methods 11: 319-324. 
# 4. Shankaran H. et al., 2012. Molecular BioSystems. 
# for plasma membrane the ref. is Hendriks 2003 (Cancer Research) and for 
endosomes (pH 6.0) from French 1995 
# 5. Kholodenko B.N. et al., 1999. The Journal of Biological Chemistry 
# 6. Blinov M.L. et al., 2006. BioSystems 
# 7. Chook, Yuh Min, et al. "The Grb2-mSos1 complex binds phosphopeptides with 
higher affinity than  
#    Grb2." Journal of Biological Chemistry 271.48 (1996): 30472-30478. 
# 8. Macdonald JL, Pike LJ (2008) Proc Natl Acad Sci USA 105: 112-117. 
# 9. Macdonald-Obermann JL, Pike LJ (2009) J Biol Chem 284: 13570-13576. 
# 10. Elleman TC et al. (2001) Biochemistry 40: 8930-8939. 
# 11. Low-Nam ST et al. (2011) Nat Struct Mol Biol 18: 1244-1249. 
# 12. Kleiman LB et al. (2011) Mol Cell 43: 723Ð737. 
# 13. Kim Y et al. (2012) Biochemistry 51 (25). American Chemical Society: 
5212–22. 
# 14. Morimatsu, Miki, et al. "Multiple-state reactions between the epidermal 
growth factor 
#  receptor and Grb2 as observed by using single-molecule analysis." 
Proceedings of the National  
#  Academy of Sciences 104.46 (2007): 18013-18018. 
# 15. Reddy, Raven J., et al. "Early signaling dynamics of the epidermal 
growth  
#  factor receptor." Proceedings of the National Academy of Sciences 113.11 
(2016): 3114-3119. 
 
 
begin parameters 
 
GRB2_total__FREE__ 3.50998295e+04 # Vary between 1e4 and 1e6 copies per cell 
SHC1_total__FREE__ 4.72130741e+05 # Vary between 1e4 and 1e6 copies per cell 
kdephos1068__FREE__ 1.83276225e+00 # Vary between 0.01 and 10 
kphos1068__FREE__ 6.23793050e-01 # Vary between 0.01 and 10 
 
 
 
# Keep constant 
 
kon__ 5.0e6 # Assumed to be 5.0e6 /M/s 
110 
 
kon_EGF__ 8.0e6 # This rate was set so EGFR phosphorylation kinetics occurs 
similarly as observed by Reddy et. al (2016) 
Kd_EGF__ 1.0e-9 # A typical value of 1 nM for the EGF dissociation constant 
was used 
ratio_kdephos__ 1.0 # Equal phosphoryaltion rates for pY1068 and pY1173 were 
assumed 
ratio_kphos__ 1.0 # Equal dephosphoryaltion rates for pY1068 and pY1173 were 
assumed 
 
 
 
 
# Avogadro constant 
NA 6.02214e23 # [=] molecules per mol 
 
# Fraction of cell to consider in a stochastic simulation 
f 1 # [=] dimensionless, 0<=f<=1  
 
 
# Cytoplasmic volume 
#   A volume of 1 to 2 pL is typical for a mammalian cell. 
Vc f*1.0e-12 # [=] L (1.0 pL) 
 
# Number of cells per dish 
numCells 1.0e7 # [=] cells per 60 mm^2 dish (10 million)  
 
# Volume of media per dish 
volMedia 1.0e-2 # [=] L (10 mL) 
 
# Volume of extracellular fluid surrounding a cell 
Vextra=f*volMedia/numCells 
 
 
GRB2_total   GRB2_total__FREE__*f # [=] molecules per cell 
EGFR_total 6.0e5*f # [=] molecules per cell (as estimated by flow cytometry 
for this CHO EGFR-GFP cells) 
SHC1_total   SHC1_total__FREE__*f # [=] molecules per cell 
 
 
 
 
# Concentration of EGF 
EGFconc 0 # [=] M 
# EGFconc 25.0e-9 # [=] M 
 
EGF_total=EGFconc*(NA*Vextra) # [=] molecules per cell 
 
 
 
 
# A typical association rate constant for a protein-protein interaction 
# A value of 1e7/M/s instead of 1e6/M/s (used originally) is closer to the on 
rate estimated in Ref. 14 , which is ~1e7-1e8/M/s 
# This value also allows off rates to be more similar to those estimated in 
Ref. 14. 
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kon kon__ # [=] /M/s 
 
kon_EGF kon_EGF__ # [=] /M/s 
 
# Dissocation and association rate constants for EGF-EGFR interaction at the 
plasma membrane 
Kd_EGF Kd_EGF__*(NA*Vextra) # [=] molecules . 1.0e-9nM 
kp_EGF=kon_EGF/(NA*Vextra) 
km_EGF=Kd_EGF*kp_EGF 
 
 
# Dissociation constant for EGFR dimerization 
#   This parameter is set so that EGFR_total/KD_dim >> 1 when number of 
receptors is high (e.g. 6.0e5) 
KD_dim 6.0e5/10 # [=] molecules per cell 
 
 
# Dissocation and association rate constants for interaction between two 
liganded (EGF-bound) receptors 
# '_pre' because off rates will be modified by a factor of 'offrate_f'. If 
offrate_f=1 then  
# 'km_dim_L_L_pre' and 'km_dim_L_L' are the same. 
km_dim_L_L_pre 0.273 # [=] /s (Ref 11) 
kp_dim_L_L=km_dim_L_L_pre/KD_dim # [=] /(molecule/cell)/s 
 
 
# Increase off rates by a factor of 'offrate_f' 
offrate_f 1.0 
km_dim_L_L=km_dim_L_L_pre*offrate_f 
 
 
 
# Kd for Grb2-SH2 domain binding to pY1068 EGFR 
Kd_GE 0.6e-6*(NA*Vc) # [=] molecules   , as estimated by Morimatsu et al. 
(2007) 
kp_GE=kon/(NA*Vc) 
km_GE=Kd_GE*kp_GE 
 
 
# Kd for SHC1-PTB domain binding to pY1173 EGFR 
Kd_SE 0.6e-6*(NA*Vc) # [=] molecules , assumed to have equal Kd as Grb2 
kp_SE=kon/(NA*Vc) 
km_SE=Kd_SE*kp_SE 
 
 
 
 
# Generic (pseudo first-order) dephosphorylation rate constant 
# From Ref. 12 we have that dephosphorylation rate of pY-EGFR on cells 
after using gefitinib is 
#  0.05/s, which corresponds to a half-life of 15 s and represents a lower  
#  bound (estimation without considering protection of sites by binding 
proteins and other influencing factors)  
#   When considering Shc binding in the paper they come with a model (M3) with 
1/sec rate for dephosphorylation (and 
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#   2/sec for phosphorylation), which is the same dephos rate I had picked to 
fit our data. 
#   Note: keep in mind that they are using 10uM of gefitinib and according to 
Ref. 13 that concentration would only 
#  inhibit 20-40% of the in vitro kinase activity of EGFR at Y1068, Y1148 and 
Y1173. 
kdephos1068 kdephos1068__FREE__ # 0.15 
 
ratio_kdephos 1.0 
kdephos1173 kdephos1068*ratio_kdephos 
 
# Generic (pseudo first-order) phosphorylation rate constant 
# Value was set to fit experimental behavior observed by SiMPull 
 
kphos1068 kphos1068__FREE__ # 0.043 
 
ratio_kphos 1.0 
kphos1173 kphos1068*ratio_kphos 
 
 
end parameters 
 
begin molecule types 
 
# Ligand, growth factor 
EGF(EGFL) 
 
# Receptor tyrosine kinase, Epidermal growth factor receptor 
#   I_III: domains I and III in the ectodomain for EGF binding 
# II: domain II for dimerization through ectodomain. Dimerization reaction 
will change state of receptor 
# from monomer (unbound) to dimer (bound), and dissociation reaction the 
opposite. 
EGFR(I_III,II~u~b,Y1068~0~P,Y1173~0~P) 
 
# Grb2 adaptor protein. SH3 represents both N- and C-terminus SH3 domains 
GRB2(SH2) 
 
#   SHC-Y317 in the p52 isoform | Y427 in the p66 isoform 
SHC1(PTB) 
 
end molecule types 
 
 
begin seed species 
 
EGF(EGFL) EGF_total 
EGFR(I_III,II~u,Y1068~0,Y1173~0) EGFR_total  
GRB2(SH2) GRB2_total 
SHC1(PTB) SHC1_total 
 
 
end seed species 
 
begin observables 
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Molecules EGF EGF() 
Molecules EGFRtot EGFR() 
Molecules Grb2tot GRB2() 
Molecules Shc1tot SHC1() 
Molecules EGFR_EGF EGFR(I_III!+) 
Molecules monR EGFR(II~u) 
Molecules dimR EGFR(II~b) 
Molecules pY1068 EGFR(Y1068~P!?) 
Molecules pY1173 EGFR(Y1173~P!?) 
Molecules Grb2_EGFR GRB2(SH2!+) 
Molecules Shc1_EGFR SHC1(PTB!+) 
 
Molecules pY1068_pY1173 EGFR(Y1068~P!?,Y1173~P!?) 
 
Molecules monR_pYpY EGFR(II~u,Y1068~P!?,Y1173~P!?) 
Molecules dimR_pYpY EGFR(II~b,Y1068~P!?,Y1173~P!?) 
 
 
 
end observables 
 
 
begin functions 
 
pY1068_percent() 100*pY1068/EGFRtot 
pY1173_percent() 100*pY1173/EGFRtot 
pYpY_per() 100*pY1068_pY1173/EGFRtot 
random_pYpY_per() 100*(pY1068/EGFRtot)*(pY1173/EGFRtot) 
 
monR_pYpY_per() 100*monR_pYpY/(monR+1) # +1 to avoid dividing by 0 
dimR_pYpY_per() 100*dimR_pYpY/(dimR+1) # +1 to avoid dividing by 0 
 
 
 
end functions 
 
 
begin reaction rules 
 
# EGF reversibly binds EGFR 
EGF(EGFL)+EGFR(I_III)<->EGF(EGFL!1).EGFR(I_III!1) kp_EGF,km_EGF 
 
 
# Dimerization of EGFR for: 
# Two EGF-bound receptors. Transition from monomer (II~u) to dimer (II~b) 
states. 
# Simplification: dimerization only happens between two EGF-bound receptors 
EGFR(I_III!+,II~u)+EGFR(I_III!+,II~u)->EGFR(I_III!+,II~b)+EGFR(I_III!+,II~b) 
kp_dim_L_L 
 
 
 
# Dissociation of EGFR dimer. 
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# Simplification: dimer dissociation occurs equally regardless of how many 
receptors are EGF-bound (remember EGF can dissociate while in a dimer) 
EGFR(II~b)->EGFR(II~u) km_dim_L_L 
 
 
 
# EGFR autophosphorylation 
#   Occurs only within a dimer 
EGFR(II~b,Y1068~0)->EGFR(II~b,Y1068~P) kphos1068 
EGFR(II~b,Y1173~0)->EGFR(II~b,Y1173~P) kphos1173 
 
# Unregulated dephosphorylation of pTyr sites 
#   (mediated by constitutively active phosphatases) 
EGFR(Y1068~P)->EGFR(Y1068~0) kdephos1068 
EGFR(Y1173~P)->EGFR(Y1173~0) kdephos1173 
 
 
# Binding of Grb2 to pY1068 in EGFR 
GRB2(SH2)+EGFR(Y1068~P)<-> GRB2(SH2!1).EGFR(Y1068~P!1) kp_GE,km_GE 
 
 
# Binding of SHC1 to pY1173 in EGFR 
SHC1(PTB)+EGFR(Y1173~P)<-> SHC1(PTB!1).EGFR(Y1173~P!1) kp_SE,km_SE 
 
 
 
end reaction rules 
 
end model 
 
begin actions 
 
generate_network({overwrite=>1}) 
 
# Save parameters and concentrations before parameter scan 
#saveParameters() 
#saveConcentrations("pre_scan") 
 
# Perform a parameter scan for EGF ligand concentrations 
#parameter_scan({suffix=>"dose_resp",parameter=>"EGFconc",par_scan_vals=>[0.05
e-9,0.1e-9,0.5e-9,1.0e-9,2.5e-9,5.0e-9,10.0e-9,50.0e-9],\ 
#                
method=>"ode",t_start=>0,t_end=>600,n_steps=>600,print_functions=>1}) 
                 
parameter_scan({suffix=>"dose_resp",parameter=>"EGFconc",par_scan_vals=>[0.05e
-9,0.167e-9,0.5e-9,1.67e-9,5.0e-9,16.7e-9,50.0e-9],\ 
                
method=>"ode",t_start=>0,t_end=>120,n_steps=>3,print_functions=>1}) 
 
 
 
# Reset parameters and concentrations to those before parameter scan 
#resetParameters() 
#resetConcentrations("pre_scan") 
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# Equilibrate for 300 seconds 
#simulate({suffix=>"equil",method=>"ode",t_start=>0,t_end=>300,n_steps=>300,pr
int_functions=>1}) 
 
 
# Add 25 nM EGF, and simulate for 300 seconds 
setParameter("EGFconc","25.0e-9") 
setConcentration("EGF(EGFL)","EGF_total") 
simulate({suffix=>"EGF_25nM",method=>"ode",t_start=>0,t_end=>300,n_steps=>300,
print_functions=>1}) 
 
end actions 
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BNGL file for model in Chapter 5 
 
begin model 
 
 
# References 
# 1. Hause et al., 2012. Plos ONE. 
# 2. Engelmann BW et al., 2014. Mol Cell Proteomics. 
# 3. Kulak NA et al. (2014) Nat Methods 11: 319-324. 
# 4. Shankaran H. et al., 2012. Molecular BioSystems. 
# for plasma membrane the ref. is Hendriks 2003 (Cancer Research) and for 
endosomes (pH 6.0) from French 1995 
# 5. Kholodenko B.N. et al., 1999. The Journal of Biological Chemistry 
# 6. Blinov M.L. et al., 2006. BioSystems 
# 7. Chook, Yuh Min, et al. "The Grb2-mSos1 complex binds phosphopeptides with 
higher affinity than  
#    Grb2." Journal of Biological Chemistry 271.48 (1996): 30472-30478. 
# 8. Macdonald JL, Pike LJ (2008) Proc Natl Acad Sci USA 105: 112-117. 
# 9. Macdonald-Obermann JL, Pike LJ (2009) J Biol Chem 284: 13570-13576. 
# 10. Elleman TC et al. (2001) Biochemistry 40: 8930-8939. 
# 11. Low-Nam ST et al. (2011) Nat Struct Mol Biol 18: 1244-1249. 
# 12. Kleiman LB et al. (2011) Mol Cell 43: 723Ð737. 
# 13. Kim Y et al. (2012) Biochemistry 51 (25). American Chemical Society: 
5212–22. 
# 14. Morimatsu M et al. (2007) PNAS  104 (46): 18013–18. 
# 15. Tujin Shi, Mario Niepel,.., Peter K. Sorger, Wei-Jun Qian, H. Steven 
Wiley.  
#     Conservation of Protein Abundance Patterns Reveals the Regulatory 
Architecture of the EGFR-MAPK Pathway. 
#   Work in preparation to be submitted to Science Signaling.  
# 16. Sun Q et al. (2010) PloS one 5, no. 9 (2010): e12819 
# 17. Reddy, Raven J., et al. "Early signaling dynamics of the epidermal 
growth  
#  factor receptor." Proceedings of the National Academy of Sciences 113.11 
(2016): 3114-3119. 
 
begin parameters 
 
 
alpha_Ub__FREE__ 1 # Vary between 20 and 100 for low Ub, or 1 and 4 for high 
Ub 
alpha_pY1045__FREE__ 1 # Vary between 1 and 100 
kub__FREE__ 5.25555397e-02 # Vary between 0.001 and 0.1 
kdeub__FREE__ 1.71408252e-02 # Vary between 0.001 and 0.1 
Kd_CE__FREE__ 2.51475699e-07 # Vary between 0.1e-6 and 10.0e-6 M (0.1 uM to 10 
uM) 
Kd_CG__FREE__ 7.23610301e-07 # Vary between 0.1e-6 and 10.0e-6 M (0.1 uM to 10 
uM) 
kc__FREE__ 2.59365139e+08 # Vary between 5E5 5E8 
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# Keep constant 
 
alpha_CE__ 1 # Vary between 1 and 2 
alpha_pYpY__ 1 # Vary between 1 and 100 
 
 
CBL_total__ 5e3 # 5,000 copies per cell (from Capuani 2015) 
kon__ 5.0e6 # Assumed to be 5.0e6 /M/s 
kon_EGF__ 0.8e7 # # This rate was set so EGFR phosphorylation kinetics occurs 
similarly as observed by Reddy et. al (2016) 
Kd_EGF__ 1.0e-9 # A typical value of 1 nM for the EGF dissociation constant 
was used 
Kd_GE__ 0.6e-6 # 600 nM as estimated by Morimatsu et al. (2007) 
kdephos1068__ 1.83276225e+00 # Estimated by fitting to SiMPull data 
kphos1068__ 6.23793050e-01 # Estimated by fitting to SiMPull data 
ratio_kdephos__ 1.0 # Equal phosphoryaltion rates for pY1045 and pY1068 were 
assumed 
ratio_kphos__ 1.0 # Equal phosphoryaltion rates for pY1045 and pY1068 were 
assumed 
 
 
 
# Scaling factors for BioNetFit 
alpha_Ub alpha_Ub__FREE__ 
 
alpha_CE alpha_CE__ 
alpha_pY1045 alpha_pY1045__FREE__ 
alpha_pYpY alpha_pYpY__ 
 
 
# Avogadro constant 
NA 6.02214e23 # [=] molecules per mol 
 
# Fraction of cell to consider in a stochastic simulation 
f 1 # [=] dimensionless, 0<=f<=1  
 
 
# Cytoplasmic volume 
#   A volume of 1 to 2 pL is typical for a mammalian cell. 
Vc f*1.0e-12 # [=] L (1.0 pL) 
 
# Number of cells per dish 
numCells 1.0e7 # [=] cells per 60 mm^2 dish (10 million)  
 
# Volume of media per dish 
volMedia 1.0e-2 # [=] L (10 mL) 
 
# Volume of extracellular fluid surrounding a cell 
Vextra=f*volMedia/numCells 
 
 
GRB2_total   1.0e6*f # [=] molecules per cell 
EGFR_total 2.5e5*f # [=] molecules per cell (3e5 from Capuani 2015) 
# Abundance of Cbl in several cell lines have been estimated to be 9,000-
15,000 copies/cell (Refs. 3 and 15) 
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CBL_total  CBL_total__*f*1 # [=] molecules per cell. (5.2e3 from Capuani 
2015) 
 
 
 
 
# Concentration of EGF 
EGFconc 0 # [=] M 
# EGFconc 25.0e-9 # [=] M 
 
EGF_total=EGFconc*(NA*Vextra) # [=] molecules per cell 
 
 
 
# A typical association rate constant for a protein-protein interaction 
# A value of 1e7/M/s instead of 1e6/M/s (used originally) is closer to the on 
rate estimated in Ref. 14 , which is ~1e7-1e8/M/s 
# This value also allows off rates to be more similar to those estimated in 
Ref. 14. 
kon kon__ # [=] /M/s 
 
kon_EGF kon_EGF__ # [=] /M/s 
 
# Dissocation and association rate constants for EGF-EGFR interaction at the 
plasma membrane 
Kd_EGF Kd_EGF__*(NA*Vextra) # [=] molecules . 1.0e-9nM 
kp_EGF=kon_EGF/(NA*Vextra) 
km_EGF=Kd_EGF*kp_EGF 
 
 
# Dissociation constant for EGFR dimerization 
#   This parameter is set so that EGFR_total/KD_dim >> 1 when number of 
receptors is high (e.g. 6.0e5) 
KD_dim 6.0e5/10 # [=] molecules per cell 
 
 
# Dissocation and association rate constants for interaction between two 
liganded (EGF-bound) receptors 
# '_pre' because off rates will be modified by a factor of 'offrate_f'. If 
offrate_f=1 then  
# 'km_dim_L_L_pre' and 'km_dim_L_L' are the same. 
km_dim_L_L_pre 0.273 # [=] /s (Ref 11) 
kp_dim_L_L=km_dim_L_L_pre/KD_dim # [=] /(molecule/cell)/s 
 
 
# Increase off rates by a factor of 'offrate_f' 
offrate_f 1.0 
km_dim_L_L=km_dim_L_L_pre*offrate_f 
 
 
 
# Kd for Grb2-SH2 domain binding to pY1068 EGFR 
Kd_GE Kd_GE__*(NA*Vc) # [=] molecules   , (2.6e-6*(NA*Vc)) from Ref. 1 
kp_GE=kon/(NA*Vc) 
km_GE=Kd_GE*kp_GE 
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# Kd for Cbl-TKB domain binding to pY1045 EGFR 
Kd_CE=Kd_CE__FREE__*(NA*Vc) # [=] molecules , (1.0e-6*(NA*Vc)) from Ref. 16 
kp_CE=kon/(NA*Vc) 
km_CE=Kd_CE*kp_CE 
 
# Kd for Cbl-PR region constitutive binding to the SH3 domains of Grb2 
Kd_CG=Kd_CG__FREE__*(NA*Vc) # [=] molecules , from Ref. 16 
kp_CG=kon/(NA*Vc) 
km_CG=Kd_CG*kp_CG 
 
# Cooperativity constant. In this case, association rates will be multiplied 
by this constant to account for the  
# increased local concentration, which in our context is the result of being 
bound to the same molecular complex 
kc kc__FREE__ 
 
# Association constants for reactions with cooperativity 
# Grb2-SH2 domain binding to pY1068 or pY1086 EGFR when Grb2 is complexed with 
a Cbl molecule bound to EGFR 
kp_GE_c=kp_GE*kc 
# Cbl-TKB domain binding to pY1045 EGFR when Cbl is complexed with a Grb2 
molecule bound to EGFR (at pY1068 or pY1086) 
kp_CE_c=kp_CE*kc 
# Cbl-PR region binding to the SH3 domains of Grb2 when both molecules are 
bound to the same receptor (Grb2 bound to pY1068 or pY1086) 
kp_CG_c=kp_CG*kc 
 
 
 
 
# Generic (pseudo first-order) dephosphorylation rate constant 
# From Ref. 12 we have that dephosphorylation rate of pY-EGFR on cells 
after using gefitinib is 
#  0.05/s, which corresponds to a half-life of 15 s and represents a lower  
#  bound (estimation without considering protection of sites by binding 
proteins and other influencing factors)  
#   When considering Shc binding in the paper they come with a model (M3) with 
1/sec rate for dephosphorylation (and 
#   2/sec for phosphorylation), which is the same dephos rate I had picked to 
fit our data. 
#   Note: keep in mind that they are using 10uM of gefitinib and according to 
Ref. 13 that concentration would only 
#  inhibit 20-40% of the in vitro kinase activity of EGFR at Y1068, Y1148 and 
Y1173. 
kdephos1068 kdephos1068__ # 0.15 
 
ratio_kdephos ratio_kdephos__ 
kdephos1045 kdephos1068*ratio_kdephos 
 
# Generic (pseudo first-order) phosphorylation rate constant 
# Value was set to fit experimental behavior observed by SiMPull 
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kphos1068 kphos1068__ # 0.043 
 
ratio_kphos ratio_kphos__ 
kphos1045 kphos1068*ratio_kphos 
 
 
# Rate of ubiquitination and de-ubiquitination 
kub kub__FREE__ # 0.03 
kdeub kdeub__FREE__ # 0.01 
 
maxValue 20 # Constant value to set max value of Y display in graph 
 
end parameters 
 
begin molecule types 
 
# Ligand, growth factor 
EGF(EGFL) 
 
# Receptor tyrosine kinase, Epidermal growth factor receptor 
#   I_III: domains I and III in the ectodomain for EGF binding 
# II: domain II for dimerization through ectodomain. Dimerization reaction 
will change state of receptor 
# from monomer (unbound) to dimer (bound), and dissociation reaction the 
opposite. 
# Lys_ub: Number of ubiquitin molecules covalently linked to lysines in 
EGFR 
EGFR(I_III,II~u~b,Y1045~0~P,Y1068~0~P,Lys_ub~0~1) 
 
# Grb2 adaptor protein. SH3 represents both N- and C-terminus SH3 domains 
GRB2(SH2,SH3) 
 
 
# CBL E3 ubiquitin-protein ligase. Tyrosine-kinase binding motif (TKB) 
contains a SH2-like domain near N-terminus. 
# Poline-rich (PR) region closer to the C-terminus  
CBL(TKB,PR) 
 
 
end molecule types 
 
 
begin seed species 
 
EGF(EGFL) EGF_total 
EGFR(I_III,II~u,Y1045~0,Y1068~0,Lys_ub~0) EGFR_total  
GRB2(SH2,SH3) GRB2_total 
CBL(TKB,PR) CBL_total 
 
 
end seed species 
 
begin observables 
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Molecules EGF EGF() 
Molecules EGFRtot EGFR() 
Molecules Grb2tot GRB2() 
Molecules Cbltot CBL() 
Molecules Cbl_EGFRpY1045 CBL(TKB!1).EGFR(Y1045~P!1) 
Molecules Cbl_notEGFRpY1045 CBL(TKB) 
Molecules EGFR_EGF EGFR(I_III!+) 
Molecules monR EGFR(II~u) 
Molecules dimR EGFR(II~b) 
Molecules pY1045 EGFR(Y1045~P!?) 
Molecules pY1068 EGFR(Y1068~P!?) 
Molecules Grb2_EGFR GRB2(SH2!+) 
 
Molecules Cbl_Grb2_comp CBL(PR!1).GRB2(SH3!1) 
Molecules pY1045_pY1068 EGFR(Y1045~P!?,Y1068~P!?) 
 
Molecules monR_pYpY EGFR(II~u,Y1045~P!?,Y1068~P!?) 
Molecules dimR_pYpY EGFR(II~b,Y1045~P!?,Y1068~P!?) 
 
Molecules EGFR_ub EGFR(Lys_ub~1) 
 
#Molecules EGFRpY1068_Grb2_Cbl_loop 
GRB2(SH2!3,SH3!1).CBL(PR!1,TKB!2).EGFR(Y1045~P!2,Y1068~P!3) 
#Molecules EGFRpY1068_Grb2_Cbl_open1 
GRB2(SH2,SH3!1).CBL(PR!1,TKB!2).EGFR(Y1045~P!2,Y1068~P) 
#Molecules EGFRpY1068_Grb2_Cbl_open2 
CBL(TKB,PR!1).GRB2(SH3!1,SH2!2).EGFR(Y1068~P!2,Y1045~P) 
#Molecules EGFRpY1068_Grb2_Cbl_open3 
CBL(PR,TKB!1).EGFR(Y1045~P!1,Y1068~P!2).GRB2(SH2!2,SH3) 
 
 
end observables 
 
 
begin functions 
 
pY1045_percent() 100*pY1045/EGFRtot 
pY1068_percent() 100*pY1068/EGFRtot 
pYpY_per() 100*pY1045_pY1068/EGFRtot 
random_pYpY_per() 100*(pY1068/EGFRtot)*(pY1045/EGFRtot) 
Cbl_EGFR_per() 100*Cbl_EGFRpY1045/Cbltot 
 
monR_pYpY_per() 100*monR_pYpY/(monR+1) # +1 to avoid dividing by 0 
dimR_pYpY_per() 100*dimR_pYpY/(dimR+1) # +1 to avoid dividing by 0 
 
BNF_Cbl_EGFR_per() alpha_CE*100*Cbl_EGFRpY1045/Cbltot 
BNF_pY1045_per() alpha_pY1045*100*pY1045/EGFRtot 
BNF_pYpY_per() alpha_pYpY*100*pY1045_pY1068/EGFRtot 
 
 
# Percent of receptors ubiquitinated 
Ubiq_EGFR_per() 100*EGFR_ub/EGFRtot 
BNF_Ub1_EGFR_per() alpha_Ub*100*EGFR_ub/EGFRtot # Ub1 is for WT 
BNF_Ub2_EGFR_per() alpha_Ub*2.5*100*EGFR_ub/EGFRtot # Ub2 is for Y1045+ mutant 
(no-cooperativity) (multiply by 2.5 because max should be 40) 
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end functions 
 
 
begin reaction rules 
 
# EGF reversibly binds EGFR 
EGF(EGFL)+EGFR(I_III)<->EGF(EGFL!1).EGFR(I_III!1) kp_EGF,km_EGF 
 
 
# Dimerization of EGFR for: 
# Two EGF-bound receptors. Transition from monomer (II~u) to dimer (II~b) 
states. 
# Simplification: dimerization only happens between two EGF-bound receptors 
EGFR(I_III!+,II~u)+EGFR(I_III!+,II~u)->EGFR(I_III!+,II~b)+EGFR(I_III!+,II~b) 
kp_dim_L_L 
 
 
 
# Dissociation of EGFR dimer. 
# Simplification: dimer dissociation occurs equally regardless of how many 
receptors are EGF-bound (remember EGF can dissociate while in a dimer) 
EGFR(II~b)->EGFR(II~u) km_dim_L_L 
 
 
 
# EGFR autophosphorylation 
#   Occurs only within a dimer 
EGFR(II~b,Y1045~0)->EGFR(II~b,Y1045~P) kphos1045 
EGFR(II~b,Y1068~0)->EGFR(II~b,Y1068~P) kphos1068 
 
# Unregulated dephosphorylation of pTyr sites 
#   (mediated by constitutively active phosphatases) 
EGFR(Y1045~P)->EGFR(Y1045~0) kdephos1045 
EGFR(Y1068~P)->EGFR(Y1068~0) kdephos1068 
 
 
# Binding of Grb2 to pY1068 in EGFR when it is free in solution, either as 
Grb2 or Cbl-Grb2 complex. 
# In the model Grb2 cannot bind to both pY1068 and pY1086 simultaneously 
# You need to specify each molecular complex specifically to avoid duplicate 
rules 
GRB2(SH2,SH3)+EGFR(Y1068~P)<-> GRB2(SH2!1,SH3).EGFR(Y1068~P!1) kp_GE,km_GE 
GRB2(SH2,SH3!1).CBL(PR!1,TKB)+EGFR(Y1068~P)<-> 
GRB2(SH2!2,SH3!1).CBL(PR!1,TKB).EGFR(Y1068~P!2) kp_GE,km_GE 
 
 
 
# Binding of CBL to pY1045 in EGFR when it is free in solution, either as Cbl 
or Cbl-Grb2 complex 
CBL(TKB,PR)+EGFR(Y1045~P) <-> CBL(TKB!1,PR).EGFR(Y1045~P!1) kp_CE,km_CE 
CBL(TKB,PR!1).GRB2(SH2,SH3!1)+EGFR(Y1045~P) <-> 
CBL(TKB!2,PR!1).GRB2(SH2,SH3!1).EGFR(Y1045~P!2) kp_CE,km_CE 
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# Constitutive association of CBL proline-rich region to the SH3 domains of 
Grb2 
# When both CBL and GRB2 are free in solution 
CBL(TKB,PR)+GRB2(SH2,SH3) <-> CBL(TKB,PR!1).GRB2(SH2,SH3!1) kp_CG,km_CG 
# When either one of them is bound to pYEGFR and the other one free in 
solution 
CBL(TKB!+,PR)+GRB2(SH2,SH3) <-> CBL(TKB!+,PR!1).GRB2(SH2,SH3!1) kp_CG,km_CG 
CBL(TKB,PR)+GRB2(SH2!+,SH3) <-> CBL(TKB,PR!1).GRB2(SH2!+,SH3!1) kp_CG,km_CG 
 
 
# Association reactions having cooperativity. The following reactions occur 
between molecules bound 
# to the same molecular complexes, this increases the local concentration of 
the reactants and therefore 
# the association rates 
 
# Cooperative binding of Grb2 to pY1068 and pY1086 in EGFR   
# In the model Grb2 cannot bind to both pY1068 and pY1086 simultaneously 
GRB2(SH2,SH3!1).CBL(PR!1,TKB!2).EGFR(Y1045~P!2,Y1068~P) <-> 
GRB2(SH2!3,SH3!1).CBL(PR!1,TKB!2).EGFR(Y1045~P!2,Y1068~P!3) kp_GE_c,km_GE 
 
# Cooperative binding of CBL to pY1045 in EGFR 
CBL(TKB,PR!1).GRB2(SH3!1,SH2!2).EGFR(Y1068~P!2,Y1045~P) <-> 
CBL(TKB!3,PR!1).GRB2(SH3!1,SH2!2).EGFR(Y1068~P!2,Y1045~P!3) kp_CE_c,km_CE 
 
# Cooperative binding of CBL proline-rich region to the SH3 domains of Grb2 
when both molecules are bount to EGFR 
CBL(PR,TKB!1).EGFR(Y1045~P!1,Y1068~P!2).GRB2(SH2!2,SH3) <-> 
CBL(PR!3,TKB!1).EGFR(Y1045~P!1,Y1068~P!2).GRB2(SH2!2,SH3!3) kp_CG_c,km_CG 
 
 
 
# Ubiquitination of EGFR when Cbl is bound to the receptor (directly or 
through Grb2 bound to pY1068 or pY1086) 
# Direct binding 
EGFR(Y1045~P!+,Lys_ub~0)->EGFR(Y1045~P!+,Lys_ub~1) kub 
# Indirect binding (pY1045 should be free and CBL should have its TKB free) 
EGFR(Y1045,Y1068~P!1,Lys_ub~0).GRB2(SH2!1,SH3!2).CBL(TKB,PR!2)-
>EGFR(Y1045,Y1068~P!1,Lys_ub~1).GRB2(SH2!1,SH3!2).CBL(TKB,PR!2) kub 
 
# De-ubiquitination of EGFR  
EGFR(Lys_ub~1)->EGFR(Lys_ub~0) kdeub 
 
 
 
end reaction rules 
 
end model 
 
begin actions 
 
generate_network({overwrite=>1}) 
 
# Save parameters and concentrations before parameter scan 
#saveParameters() 
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#saveConcentrations("pre_scan") 
 
                 
parameter_scan({suffix=>"dose_resp",parameter=>"EGFconc",par_scan_vals=>[0.05e
-9,0.167e-9,0.5e-9,1.67e-9,5.0e-9,16.7e-9,50.0e-9],\ 
                
method=>"ode",t_start=>0,t_end=>120,n_steps=>3,print_functions=>1}) 
 
# Eliminate Grb2 binding and therefore cooperative recruitment of Cbl 
setParameter("kp_GE",0.0); 
parameter_scan({suffix=>"dose_resp_no_coop",parameter=>"EGFconc",par_scan_vals
=>[0.05e-9,0.167e-9,0.5e-9,1.67e-9,5.0e-9,16.7e-9,50.0e-9],\ 
                
method=>"ode",t_start=>0,t_end=>120,n_steps=>3,print_functions=>1}) 
 
 
# Reset parameters and concentrations to those before parameter scan 
#resetParameters() 
#resetConcentrations("pre_scan") 
 
# Equilibrate for 300 seconds 
#simulate({suffix=>"equil",method=>"ode",t_start=>0,t_end=>300,n_steps=>300,pr
int_functions=>1}) 
 
 
## Add 25 nM EGF, and simulate for 300 seconds 
#setParameter("EGFconc","25.0e-9") 
#setConcentration("EGF(EGFL)","EGF_total") 
#simulate({suffix=>"EGF_25nM",method=>"ode",t_start=>0,t_end=>30,n_steps=>50,p
rint_functions=>1}) 
 
end actions 
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APPENDIX C: Configuration files for parameter estimation (.conf) 
 
Configuration file for model in Chapter 4 
 
############# 
### PATHS ### 
############# 
 
# The directory to which job output will be written 
output_dir=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/output/ 
 
# The BioNetGen executable 
# bng_command=Simulators/BNG2.pl 
bng_command= 
/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/Simulators/BNG2.pl 
 
# ESC added the following two lines because NFsim was not able to run 
simulations 
# NFsim for Cygwin 
#nfsim_dir=/home/esc1987/Modeling/NFsim_v1.11/bin 
#nfsim_command=NFsim_x86_64-cygwin 
#nfsim_command=NFsim_i686-cygwin 
 
# The model file to be used in fitting simulations 
model=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/CHO_EGFR/fit
_v1_16/180222_CHO_EGFR.bngl 
 
 
# The experimental data to be fit 
exp_file=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/CHO_EGFR/
fit_v1_16/dose_resp.exp 
exp_file=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/CHO_EGFR/
fit_v1_16/EGF_25nM.exp 
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####################### 
### General Options ### 
####################### 
 
# The job name 
job_name=fit_v1_16_2 
 
# Whether or not to generate plots for best-fit outputs 
make_plots=0 
 
# Number of simulations to run in parallel. 
# Change parellel_count to the number of CPU cores on your machine for 
increased performance. 
parallel_count=5 
 
# Kill a job and continue without it if  process runs longer than walltime. Adjust if 
needed. 
max_walltime=10:00 
 
# Delete files that are no longer needed to save disk space 
# Property not working 
delete_old_files=1 
 
# Ask if you want to overwrite existing existing job output. In this case disable 
ask, that way you can do batch fitting 
 
 
####################### 
### Fitting Options ### 
####################### 
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# Which objective function to minimize in fitting. A complete list of objective 
functions is described in GenFit documentation. 
# 1:  sum-of-squares function (i.e. nonlinear least squares fitting). 
# 2 chi-square function (i.e. weighted nonlinear least squares fitting) 
objfunc=1 
 
# Do not divide by initial value (at t=0) of simulation results 
divide_by_init= 0 
 
# The maximum number of generations to run. 
max_generations=75 
 
# The number of unique parameter sets simulated in first generation. 
first_gen_permutations=150  
 
# The number of unique parameter sets simulated in a generation. 
permutations=75 
 
# Do bootstrapping 
bootstrap= 100 
bootstrap_chi= 30 
 
 
# The mutation probability and mutation factor for free parameters. 
mutate=default 0.2 0.2 
 
# The free parameters. These are generated on a random log scale between 
numbers indicated. 
loguniform_var=GRB2_total__FREE__ 1E4 1E6 
loguniform_var=SHC1_total__FREE__ 1E4 1E6 
loguniform_var=kdephos1068__FREE__ 0.5 5 
loguniform_var=kphos1068__FREE__ 0.5 5 
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Configuration file for model in Chapter 5 
 
############# 
### PATHS ### 
############# 
 
# The directory to which job output will be written 
output_dir=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/output/ 
 
# The BioNetGen executable 
# bng_command=Simulators/BNG2.pl 
bng_command= 
/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/Simulators/BNG2.pl 
 
# ESC added the following two lines because NFsim was not able to run 
simulations 
# NFsim for Cygwin 
#nfsim_dir=/home/esc1987/Modeling/NFsim_v1.11/bin 
#nfsim_command=NFsim_x86_64-cygwin 
#nfsim_command=NFsim_i686-cygwin 
 
# The model file to be used in fitting simulations 
model=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/CHO_EGFR/fit
_v1_17/180301_HeLa_EGFR_Cbl_Ub.bngl 
 
 
# The experimental data to be fit 
exp_file=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/CHO_EGFR/
fit_v1_17/dose_resp.exp 
exp_file=/home/esc1987/Modeling/BioNetFit_v1.1_with_Simulators/CHO_EGFR/
fit_v1_17/dose_resp_no_coop.exp 
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####################### 
### General Options ### 
####################### 
 
# The job name 
job_name=fit_v1_17 
 
# Whether or not to generate plots for best-fit outputs 
make_plots=0 
 
# Number of simulations to run in parallel. 
# Change parellel_count to the number of CPU cores on your machine for 
increased performance. 
parallel_count=6 
 
# Kill a job and continue without it if  process runs longer than walltime. Adjust if 
needed. 
max_walltime=10:00 
 
# Delete files that are no longer needed to save disk space 
# Property not working 
delete_old_files=1 
 
# Ask if you want to overwrite existing existing job output. In this case disable 
ask, that way you can do batch fitting 
 
 
####################### 
### Fitting Options ### 
####################### 
 
# Which objective function to minimize in fitting. A complete list of objective 
functions is described in GenFit documentation. 
# 1:  sum-of-squares function (i.e. nonlinear least squares fitting). 
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# 2 chi-square function (i.e. weighted nonlinear least squares fitting) 
objfunc=1 
 
# The maximum number of generations to run. 
max_generations=75 
 
# The number of unique parameter sets simulated in first generation. 
first_gen_permutations=150 
 
# The number of unique parameter sets simulated in a generation. 
permutations=75 
 
# Do bootstrapping 
bootstrap= 6 
bootstrap_chi= 35 
 
# Do not divide by initial value (at t=0) of simulation results 
divide_by_init= 0 
 
 
# The mutation probability and mutation factor for free parameters. 
mutate=default 0.2 0.2 
 
 
# The free parameters. 
# These are scaling factors generated on a random scale between numbers 
indicated. 
#random_var=alpha_pY1045__FREE__ 4 20 
#random_var=alpha_Ub__FREE__ 20 100 
random_var=alpha_pY1045__FREE__ 1 100 
random_var=alpha_Ub__FREE__ 6 60 
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# These are generated on a random log scale between numbers indicated. 
loguniform_var=Kd_CE__FREE__ 0.1E-6 10.0E-6 
loguniform_var=Kd_CG__FREE__ 0.1E-6 10.0E-6 
loguniform_var=kc__FREE__ 5E5 5E8 
loguniform_var=kub__FREE__ 0.001 0.1 
loguniform_var=kdeub__FREE__ 0.001 0.1 
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